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ABSTRACT 
Glioblastoma (GBM), the most malignant of brain tumors, has been classified on the basis of 
molecular signature into four subtypes: classical, mesenchymal, proneural and neural, among 
which the mesenchymal and proneural subtypes have the shortest and longest survival, 
respectively. Here we show that the transcription factor PATZ1 gene is upregulated in gliomas 
compared to normal brain and, among GBMs, is particularly enriched in the proneural subtype 
and co-localize with stemnessmarkers. Accordingly, in GBM-derived glioma-initiating stem cells 
(GSCs) PATZ1 is overexpressed compared to differentiated tumor cells and its expression 
significantly correlates with the characteristic stem cell capacity to grow as neurospheres in 
vitro. Interestingly, survival analysis demonstrated that PATZ1 lower levels informed poor 
prognosis in GBM and, specifically, in the proneural subgroup, suggesting it may serve a role as 
diagnostic and prognostic biomarker for intra-subtype heterogeneity of proneural GBM. We also 
show that PATZ1 suppresses the expression of the mesenchyme-inducer CXCR4, and that PATZ1 
and CXCR4 are inversely correlated in GSC and proneural GBM. Overall these findings support a 
central role of PATZ1 in regulating malignancy of GBM. 
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INTRODUCTION 
1. Gliomas and oligodendrogliomas 
1.1 Epidemiology and classification 
Central Nervous System (CNS) tumors are relatively rare, representing 2% of all malignant 
tumors in the adult, while in the young age they represent the second in terms of frequency after 
leukemia, accounting for 20% of all neoplasms. 
Diffuse astrocytic tumors (grades II-IV sec WHO) include 60% of all intracranial primitive 
tumors, with an annual incidence of 3.19/100,000 for  glioblastomas and 0.5/100,000 people for 
diffuse astrocytomas, in the US population (1). In Europe, there is an average incidence of 3 
cases/100,000 per year in Eastern Europe and 5/100,000 per year in the United Kingdom and 
Ireland (2). The country with the highest incidence of diagnosis of brain tumors is Albania, with 
the lowest in Cyprus (3). There is a slight predominance among males (1.3: 1) and although 
these can occur at any age, the risk increases substantially in the older age. Older patients are 
more likely to be affected by higher-grade gliomas, especially glioblastoma.  
For decades, primitive CNS tumors have been classified on the basis of histological criteria by 
identifying tumor categories depending on their microscopic resemblance to presumed cells of 
origin and their degree of differentiation; tumors are classified into gliomas, meningiomas, 
neuronal, embryonic or poorly differentiated tumors. 
Gliomas then, based on the glial cell of origin, have been classified into astrocytomas, 
oligodendrogliomas and ependymomas. Astrocytomas, based on  their ability to infiltrate 
adjacent tissue and on histologic characteristics,  are classified into WHO grade I 
(pilocyticastrocytoma) to WHO grade IV (glioblastoma) forms. 
In adults, the most frequent cerebral malignant neoplasm is glioblastoma (GBM), accounting for 
about 15% of all intracranial tumors and 45-50% of the primitive brain tumors. 
In 2016 [4], the World Health Organization drafted a new Classification of the Tumors of the 
CNS, which, albeit innovative in its approach, is a revision of the previous fourth edition of 2007 
[5], rather than a fifth edition. 
For the first time, the new classification scheme was based on the combination of histological 
and molecular parameters, thus providing greater objectivity for diagnosis and better 
understanding of tumor biology, despite, according to the current state of the art, key diagnostic 
criteriaare still histological. 
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The WHO classification system represents an evolution of the grading scheme proposed by the 
St. Anne and Mayo Clinic hospitals, originally formulated for needle biopsy samples and using a 
system based on the presence/absence of four variables: nuclear atypia, mitosis, microvascular 
proliferation and necrosis (Figure 1) 
 
 
 
 
 
 
 
 
 
This new approach has allowed us to recognize new classification entities, and to abolish instead 
others, and has allowed to group different tumors on the basis of their clinical-pathological 
significance. 
An example, in this sense, is represented by the category of diffuse gliomas, which group all the 
gliomas presenting with infiltrative characters, irrespective of their cellular origin: if, in the past, 
that of infiltrating astrocytoma was a separated entity from that of infiltrating 
oligodendroglioma, now it falls into the same category, thus encompassing WHO grade II and 
grade III astrocytic tumors, WHO grade II and III oligodendrogliomas, oligoastrocytomas, grade 
IV glioblastoma and diffusegliomas of childhood. 
Within this new and large family, a key distinction is based on the search of isoenzyme 
dehydrogenase (IDH)mutations, allowing differentiation into IDH-mutated and IDH-wildtype 
tumors, depending on whether or not is present the R132H IDH1mutated protein or mutations 
of codon 132 for IDH1 and codon 172 for IDH2 (in clinical practice, the detection of IDH1 R132H 
mutation is enough to define the tumor as IDH-mutated). If it is not possible to evaluate the 
presence of mutations or the results are ambiguous, IDH-NOS definition (nototherwisespecified) 
is adopted (Figure 2). 
Figure 1.  Four variables in the grading system according to Saint Ann-Mayo Clinic:  
a. nuclear atypia; b. mitotic activity; c. pseudopalisading necrosis; d. microvascular proliferation 
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The distinction between IDH-mutated and IDH-wildtypetumors has a predominantly prognostic 
value, being the prognosis of IDH-mutated glioblastomas better than the wildtype counterpart.  
Further molecular aspects may be added to the determination of the IDH pattern in order to 
achieve a complete definition of an “integrated diagnosis”. 
1.2 Glioblastoma IDH-wildtype 
Epidemiology and etiology 
Glioblastoma IDH-wild type accounts for about 90% of all glioblastomas. 
It may be defined as a high grade glioma with astrocytic predominant differentiation 
characterized by nuclear atypia, cell pleomorphism, high mitotic activity, diffuse growth pattern 
with microvascular proliferation and/or necrosis, in absence of IDH mutations. It is also named 
primary glioblastoma, because it originates de novo without progressing from a low grade lesion.  
Many studies have been conducted to understand the etiology of glioblastomas without 
achieving univocal and definitive conclusions. Controversial is the role of non-ionizing radiations 
(egmobile phones) and professional exposure, while head and neck exposure toionizing 
radiation seems to be the only valid risk factor; conversely, a history of allergy or atopy seems to 
have a protective role. 
Genetic susceptibility has also been demonstrated, resulting from cases of glioblastomas 
diagnosed in more than one member of the same family: this predisposition is due to the 
presence of hereditary tumor syndromes such as Type 1 Turcot syndrome, Li-Fraumeni 
Figure 2.  Diagnostic flowchart (2016 WHO) 
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syndrome and type 1 neurofibromatosis. Five independent studies have then shown a 
fundamental role of several genes (TERT, EGFR, TP53) to increase the risk of glioblastoma. 
The origin of glioblastoma is still being studied to date: if the hypothesis of dedifferentiation 
from astrocytic precursors is valid, the discovery of cancer stem cells that are similar to normal 
brain stem cells of thesubventricularzone has opened another research path [6]. 
Tumor stem cells are able, like all stem cells, to cause an asymmetric division, generating cells 
that will begin the differentiation process. It is believed that these cells are nothing but neural 
stem cells - as also demonstrated by the expression of CD133, Sox2, Musashi and Nestin stem 
cell markers. Based on the evaluation of the expressed markers, two subgroups of tumor stem 
cells were identified: Type 1 cells, with proneural phenotype, resemble fetal stem cells, are 
CD133 and CD15 positive and have the ability to form non-adherent spheres; Type 2 cells, with 
mesenchymal phenotype, are instead CD44 positive but CD133 negative, more invasive and with 
semi-adherent growth.  
However, the presence of negativity for CD133 should not be misleading: these cells may force 
the classic criteria ofstemnessand give rise to positive CD133 cells; the expression of CD133 and 
stem behavior, therefore, must be evaluated in the light of an evolutionary process dependent 
also on environmental factors including the hypoxia, that is observed in stemness niches. 
Consequently, the use of CD133 as the sole marker of stemness and tumor aggression is 
unsuitable and should be evaluated in the context of the ability to form spheres and invade 
adjacent tissues.Since these stem cells are resistant to common therapeutic approaches and 
therefore responsible for disease progression, they could be used as a target for a new targeted 
therapy: early studies assessed the effect of an EGFR inhibitor (cetuximab) on tumor growth, 
focusing on vIII-EGFR mutated form, that is constitutively active and which increases 
proliferation by inhibiting apoptotic processes. Paradoxically, probably because an inhibitor is 
available, it has been shown that the presence of EGFRvIII correlates with better prognosis, 
while its absence is associated to resistance to standard chemotherapy. In addition, when 
present, EGFRvIII is mostly expressed by stem cells but not by the traditional cell lines that, once 
they move to the differentiation process, they quickly lose its expression.In these cases, 
therefore, treatment with cetuximab is completely ineffective and for this reason attention has 
been shifted towards signaling paths such as PI3K/Akt; CD133, in fact, forms a structural 
complex that stabilizes the PI3K regulatory p85 subunit on the cell membrane, contributing to 
increase its enzymatic activity. Subject of studies are also other tyrosine-kinase receptors such 
as VEGFR, PDGFR and the CXCR4 receptor for chemokines, that are crucial promoters of 
Proneural and Mesenchymal phenotypes. 
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Clinical aspects and localization 
IDH-wildtype glioblastoma is generally localized in the subcortical white matter and in the gray 
matter of the cerebral hemispheres, involving temporal lobe in 31% of cases, parietal lobe in 
24%, frontal lobe in 23% and occipital lobe in 16% of cases: it is highly probable, therefore, that 
the first clinical manifestation of glioblastoma is a focal neurologic deficit. In general, the tumor 
has a trend to infiltrate the adjacent cortex and, through the callous body, the contralateral 
hemisphere. The involvement of basal ganglia and thalamus is common mainly in children, 
whereas brainstem, cerebellum and spinal cord glioblastomas are rare. 
IDH-wild type glioblastoma has rapid growth associated with edema and increased intracranial 
pressure which can cause nausea, vomiting, neuro-cognitive and behavioral changes, seizures 
and marked pulsating head pain. Generally, the average time between the onset of the first 
symptom and diagnosis is three months (68% of cases, 84% within six months). 
Genetic profile 
The evolution of normal cells to tumor cells is a multi-stage process where genetic 
mutations,that are progressively acquired, determine a continuum in the disease. 
The most frequent chromosome abnormalities in glioblastomas are amplification of 
chromosome 7p (in some cases amplification may also involve chromosomes 19 and 20) and 
loss of chromosome 10q (less frequently also chromosomes 9 and 13). 
EGFR gene is amplifiedin more than 40% of cases in primary glioblastomas and rarely in 
secondary forms. This amplification is often associated (25%) with a mutation of the 
extracellular domain of EGFR, hesitating in a constitutively activated receptor known as 
EGFRvIII.Tyrosine kinase-dependent signaling alterations are present in 90% of cases and, in 
addition to EGFR amplification, a key role is to be recognized to PDGFRɑ (15%), MET (5%) and 
mutations of FGFR1-TACC1 fusion protein. The mutation and amplification of PI3K genes (eg 
PIK3CA, PIK3R1) occur in less than 10% of cases, while frequently mutated (15-40%, almost 
exclusively in primary glioblastomas) is PTEN gene, involved in cell proliferation and in the 
migration and invasion mechanisms. NF1 mutations are present in approximately 20% of cases. 
TP53 alterations are present in 25% of primary glioblastomas, while they reach 90% of 
secondary forms, wherethey are considered a distinctive and early evolutionary element, being 
also present in low grade lesions from which glioblastoma will evolve. In 10% of primary 
formswithout TP53 mutations, it is possible to identify MDM2 amplification that represents an 
alternative mechanism of evasion of p53-mediated cellular control. 
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The locus CDKN2A encodes for distinct proteins including p14ARF, which binds MDM2 and 
inhibits MDM2-mediated p53 degradation: loss of p14ARF expression is observed in nearly 50% 
of cases, as a result of the methylation of the promoter or homozygous deletion of the locus. This 
deletion is mutually exclusive with alterations of RB1, whose methylation of the promoter, 
results in its reduced expression, and appears to be more frequent in secondary glioblastomas 
(43%). 
TERT gene promoteris mutated in about 80% of primary glioblastomas, in the absence of TP53 
mutations: this alteration fails in the recruitment of a multimeric GABP protein, that behaves as 
a specific transcription factor for the mutated promoter, causing an aberrant expression of 
TERT; in secondary forms, IDH-mutated, telomere maintenance is more dependent on the 
mutations of  ATRX and TERT genes. 
IDH1 and IDH2 mutations are rare in primary glioblastoma: in case of IDH1 mutation, it is 
possible that glioblastoma is not really primary but resulting from a low-grade silent, 
undiagnosed lesion, and become apparent only in phase of progression. In primary forms, 
however, the mutations of the genes involved in chromatin remodeling are frequent, so that 
even in the absence of direct genetic alterations, epigenetic modifications may modulate gene 
expression. One of the fundamental functions of this regulation, in fact , is to keep intact some 
portions of the genome by compacting chromatin and making it inaccessible to the transcription 
mechanisms.Mutations of PRC2 and its catalytic subunit EZH2 are involved in this process. 
Another possible mechanism is silencing of DNA through the methylation of the promoters of 
some genes; the most frequently methylated gene (40-50%) is MGMT (O6-Methylguanine-DNA-
methyltransferase), that codifies for a DNA repair protein, with a predictive role for the success 
of alkylating agents (temozolomide): if the promoter is hypermethylated, there will be a 
reduction in protein synthesis with reduced damage repair induced by chemotherapy, and hence 
sensitivity to treatment. 
Based on the gene expression, it is possible to outline a molecular classification by identifying 
four subtypes of glioblastoma: classical, mesenchymal, proneural and neural [7]. 
Classical glioblastoma presents typical glioblastoma alterations, as amplification of chromosome 
7 - also present in tumors of the other classes, in varying percentages - and loss of chromosome 
10. Atypical molecular feature of this variant is the amplification of EGFR observed in 97% of 
cases; mutation of TP53 is almost always lacking. In 94% of cases, in association with EGFR 
amplification, there is homozygous focal deletion of Chr 9p21.3, centered on CDKN2A gene 
encoding for both p12INK4A and p14ARF; NESTIN stem cell marker is highly expressed, as well 
as NOTCH and Sonic-hedgehog signaling paths are activated. 
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In mesenchymal glioblastoma predominates the deletion of the 17q11.2 region containing the 
NF1 gene, resulting in its reduced gene expression: this condition is associated with a variety of 
tumors including neurofibromas, which originate from Schwann's cells and, although these cells 
are absent in the CNS, mesenchymal glioblastoma has its typical markers as S100A and microglia 
markers; frequent are the NF1/PTEN co-mutations. This variant expresses mesenchymal 
markers such as CHI3L1 (also known as YKL40, a glycoprotein involved in tissue remodeling, 
flogosis, fibrosis, asthma, and solid tumors), along with classical astrocytic markers such as 
CD44 and MERTK; highly expressed are the genes involved in the signaling pathways of TNF and 
NFKB (TRADD, RELB, TNFRSF1A). 
Proneural glioblastoma shows, as peculiar aspects, the alteration of PDGRFα gene and the point 
mutation of IDH1; in particular, the focal amplification at locus 4q12 which results in increased 
PDGFRα gene expression, is found in all glioblastomas, but with higher values in the proneural 
variant. TP53 mutations are frequent, while classical amplification of chromosome 7, associated 
with loss of chromosome 10, occurs in only 54% of cases: the pattern of alterations thus 
constitutes the characteristic of a secondary form of glioblastoma. This variant has a high 
expression of oligodendrocyte development (such as NKX2-2 and OLIG2, which inhibit the 
oncosoppressor p21, thus favoring proliferation) and proneural genes (SOX, DCX, DLL3, ASCL1, 
TCF4); frequent mutations are also those involving PIK3CA/PIK3R1. 
Neural glioblastoma is identified by the expression of neural markers (NEFL, GABRA1, SYT1, 
SLC12A5) which, together with the unequivocal aspect of optical microscopy, suggests a well-
differentiated phenotype. 
Such classification has proved to be of fundamental therapeutic value, as intensive radio-
chemotherapy treatment with adjuvant therapy (three consecutive chemotherapy cycles) 
results in a confirmed reduction of mortality in classical and mesenchymal variants, only 
hypothetical in the neural variant and absent in the proneural. MGMT methylation state is not 
associated with a specific subclass. 
Macroscopic and microscopic features 
Despite the short time of the symptoms before the diagnosis, glioblastoma often appears as a 
large, infiltrating mass, occupying sometimes more than one lobe, but tendentiallymonolaterally; 
by the time, it begins to cross the callous body by following the myelinated fibers to extend 
bilaterally. 
Most glioblastomas appear as an intraparenchymal lesions with epicenter into the white matter, 
and only rarely they are superficial and in contact with the leptomeninges and the dural 
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meninges: in this case, differential diagnosis with metastatic carcinoma or extra-axial 
lesions,such as meningioma, is essential. Infiltration of peritumoral parenchyma by single cells is 
almost always observed.  
Glioblastoma is poorly delimited, with a variable cut surface relative to the cerebral parenchyma. 
The tumor mass generally appears with a central necrotic yellowish area that can occupy up to 
80% of the total mass and with foci of hemorrhage, which, if extended, may cause stroke 
symptoms that may represent the first event of the disease; there may also be macroscopic cysts 
containing a turbid fluid representing necrotic liquefied tissue.  
Glioblastoma of the brainstem, that is haemorrhagic and necrotic as in the supratentorial form, 
tends to move forward the basilar artery, extending along the fibers of the middle cerebellar 
peduncle; spinal glioblastoma, that is rare, is often diagnosedwhen there is alreadya significant 
local or distant involvement. 
Microscopically, glioblastoma appears as a tumor with  high cellular density, is composed by 
poorly differentiated and pleomorphic cells with high mitotic activity, microvascular 
proliferation and/or necrosis. In the past, glioblastoma was termed "multiforme" to highlight the 
cellular variety that can compose the tumor mass and that can cause diagnostic problems, since 
a biopsy obtained in stereotyping may not correspond to a valid representative sample of the 
entire lesion. 
Besides the prevalent tumor cell type in the lesion, it is possible to identify and distinguish, cells 
with frankly astrocytic features. The transition between these cellular populations may be 
progressive or abrupt, especially if there is an emergence of a new tumor clone after acquiring 
further genetic mutations. 
Recognizing the cell variety is important because a lesion with high polymorphism, well-defined 
plasma membranes, and absence of cellular processes can be exchanged for metastatic 
carcinoma or melanoma; sometimes, a cellularcomponent can be so predominant as to identify a 
specific phenotypic category of glioblastoma. 
Small cell glioblastoma is characterized by small round or slightly elongated cells with 
hyperchromic nuclei and poor cytoplasm, nuclear atypia and intense mitotic activity. The Ki-67 
proliferation index is high and with immunohistochemical approach it is possible to identify fine 
GFAP+ cellular processes; it is to be considered that GFAP often has cross-reactivity with 
keratins (antibodies CK AE1 / AE3). Positivity for nestin may be observed, as well as 
amplification of EGFR (70% of cases) and loss of chromosome 10 (95%); in all primary 
glioblastomas, instead, IDH mutations are absent. 
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Glioblastoma with primitive neuronal component has one or more nodules with neuronal 
differentiation, although most of the lesions present a typically astrocytic nature. These neuronal 
foci are markedly separated from the surrounding areas and exhibit increased cellularity with 
high nucleus/cytoplasmratio; positivity for neuronal markers (egsynaptophyses), reduction in 
GFAP expression, loss of long arm of chromosome 10 and an elevated Ki-67 proliferation index, 
comparable to that of the entire lesion, can be detected. Peculiar is the tendency to disseminate 
through liquor (30-40%); about one-fourth of these lesions develop from a low grade form, and 
is therefore classified as secondary glioblastomas, IDH-mutated. 
Occasionally, glioblastomas may show anoligodendroglial component that, despite being 
associated with better prognosis, is not considered in the new classification as a distinct 
diagnostic entity. Conversely, glioblastoma with a gemystocytic component can be observed, 
meaning cells with short and radiated processes and with abundant non-fibrillary cytoplasm 
that tends to dislocate the nucleus to the periphery. Positivity for GFAP accumulates at the 
periphery and is lacking in the central hyaline region that is rich in intracytoplasmic organelles; 
in contrast, active proliferating cells exhibit a large hyperchromic nucleus with poor cytoplasm.  
Giant cells, as they are usually considered a distinctive mark of glioblastoma, if predominant in 
the tumor mass, they may identify a giant cell glioblastoma variant that seems to be related to 
better prognosis: indeed, large cells are considered the effect of a regressive process rather than 
index of high clinical aggressiveness. This variant is characterized by a high cellular 
polymorphism, with lymphocytes interposed between tumor cells in a collagen and reticulin rich 
background; frequent are the mutations of TP53, while rare is the amplification of EGFR. 
Granular cell glioblastoma is characterized by the presence of cells with granular cytoplasm that 
is Shiff Periodic Acid positive, which are important to be recognized because, when 
predominant, in rare cases, they can simulate a granular cell tumor of the pituitary gland. 
Another important distinction to be done is with macrophages: in a context of perivascular 
inflammation, in fact, tumor cells may be confused with macrophages and thus evoke a 
demyelinating disease rather than a neoplastic lesion, especially because the granular content 
can display positivity to macrophage markers such as CD68, but not for more specific markers 
such as CD163. 
Tumor mass may also contain cells with foamy cytoplasm which are distinct from adipocytes 
and which, if grouped into lobules, may suggest adipose tissue; it is also possible that there are 
foci of glandular structures with cells with a big ovalar nucleus, with prominent nucleoli, 
rounded cytoplasm, low GFAP positivity, and expression of epithelial markers: in this case the 
definition of adenoid glioblastomas is justified. However, if there is an extensive mesenchymal 
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component, with expression of alpha-1-antitrypsin, actin and EMA, the diagnosis of gliosarcoma 
may be considered. 
It is possible that cancer cells may align and accumulate in the subpial region of the cortex, in the 
subependimal area or around blood vessels and neurons (satellitosis): this distribution, defined 
as secondary structure, is the result of interaction between glioma cells and brain structures and 
is highly diagnostic for an infiltrating glioma. 
Glioblastoma is characterized by intense mitotic activity and, despite a large intertumoral and 
intratumoral variability, Ki67 proliferation index is never lower than 15-20%, with possible 
focal values of more than 50%. The lowest degree of proliferation was found in tumors with 
marked gemystocyte component, although a relationship between the proliferative index and 
clinical outcome has not been demonstrated. 
Abundant tumor vascularization is due to mechanisms of involvement of preexisting vascular, 
budding angiogenesis from existing vessels and vasculogenesis through recall of bone marrow 
cells. The basic element behind the angiogenesis is hypoxia which, through Hypoxia-Induced 
Factor 1-alpha (HIF1α), determines the activation of over 100 hypoxia-regulated genes, 
including angiogenesis-controlling proteins (VEGFA, which is the most important mediator, 
angiopoietin, IL8), cellular metabolism (carbon dioxide, lactate dehydrogenase), survival and 
apoptosis and migration (CXCR4). In this process of vascular remodeling also pericytes and cells 
derived from the bone marrow are involved . 
Two different patterns of microvascular proliferation can be identified: glomeruloid body and 
endothelial hyperplasia. 
The glomeruloid body is so named because of its resemblance to a glomerulus, given by 
mitotically active endothelial cells arranged in multiple layers together with smooth muscle 
cells/pericytes. This proliferation is much more marked nearby the necrosis, and is oriented 
towards it in response to factors released by ischemic tumor cells. A common feature is vascular 
thrombosis, responsible for the so-called "black veins" and involved in the ischemia of tumor 
tissue. Proliferating endothelial cells are positive for CD31, CD34 and VEGFR2, but negative for 
SMA (smooth muscle actin), and are surrounded by basal lamina and an incomplete pericytic 
layer, that is negative for CD31 and CD34 and positive for SMA and PDGFRB. 
The second type of vascular proliferation is the so-called hyperplasia or endothelial, 
intraluminal proliferation, with endothelial cells inside small and medium caliber vessels (not 
necessarily microvascular), resulting in a single reduced or even obliterated lumen; albeit more 
rare, this variant has a major prognostic meaning, correlating with a worse prognosis. 
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Alongside vascular proliferation, necrosis is the other essential aspect of glioblastomas and its 
presence is one of the most important predictors of aggressive behavior. It is highlighted by 
neuroimaging techniques as a hypodense nucleus within a contrasting enhancing region and can 
occupy up to 80% of the tumor mass: the greater the necrotic portion, the less the survival. 
Tumor cells are collected along the margins of necrotic lesions producing a clinically defined 
palisading appearance.In the past, it was named “pseudopalisading”, to point out how tumor 
cells did not aggregate around the necrotic region but were the remains of a tumor mass that 
went to central necrotic degeneration. Recent studies, based primarily on HIF1α expression 
evaluation and other hypoxia-induced factors, have shown that tumor cells are actually actively 
migrating around the necrotic region, driven mainly by the hypoxic environment that is 
emerging: in this pattern, therefore, vascular invasion by tumor cells results in thrombotic 
phenomena,causing necrosis and tissue hypoxia that makes tumor cells migrate to the periphery 
of the necrotic region by releasing hypoxia-induced angiogenetic factors that determine 
microvascular proliferation, present throughout the injury, but much more evident especially in 
its periphery. 
This high cellular and abnormal external region corresponds to the contrast enhancing ring 
region seen at the MRI (magnetic resonance imaging) and represents an appropriate target for 
the lesion sampling. 
In the context of tumor lesion, there are also inflammatory cells, especially in the glioblastoma 
showing marked gemystocytic component. The most represented cells are microglia cells and 
CD8 + T lymphocytes, followed by CD4 +T lymphocytes and B lymphocytes, identifiable in less 
than 10% of cases; it has also been shown that a massive infiltrate of T CD8 + lymphocytes is 
more frequent in patients with higher survival. 
Differential diagnosis 
Neoplastic diagnosis is based on the recognition of cell number and atypia, such as nuclear 
pleomorphism or hyperchromasia, p53 proteinimmunodetection, 
immunohistochemicalevaluation of mutated EGFRvIII, and the search for characteristic 
chromosomal losses and of EGFR amplification. 
Once established to be frankly neoplastic tissue, it is necessary to determine whether it is a 
primary form or a metastasis: metastatic tumors evolve from the stage of large-scale tumor 
microemboli that dislocate more than infiltrate brain tissue, unlike the obvious infiltrating 
nature of a glioblastoma, especially in the periphery; however, it is not to be excluded a priori 
that a metastasis can follow the course of the vessels and infiltrate the parenchyma by 
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simulating a glioma: in this case infiltration is generally limited and not widespread. Reactive 
astrocytes, moreover, are less frequently incorporated into the substance of a metastasis in 
which, generally, necrosis tends to save the vessels. Also useful are the cytological features that 
are typical of a glioblastoma, such as the presence of small, slightly differentiated or distinct 
astrocytic cells with little or no tendency to nuclear remodeling, small nucleoli and cellular and 
nuclear pleomorphism. Small cells of a glioblastoma are often smaller than those of a small cell 
carcinoma, and are found on a finely fibrillated background composed of neoplastic cellular 
processes blended with residues of white matter. 
Within primitive CNS tumors, it is important to differentiate between glioblastomas and 
ependymomas (often positive for EMA), oligodendrogliomas (if anaplastic can simulate a 
glioblastoma), pilocytic astrocytoma and pleomorphic xantoastrocytomas (cellular 
pleomorphism is often considered an anaplasic indicator): it is the response of cells that at least 
partially retain the characteristics of the starting cells to allow adequate differential diagnosis, in 
addition to a valid immunohistochemical evaluation. 
Finally, it is important to differentiate diagnosis from a primitive CNS lymphoma, especially in 
elderly patients with intracerebral invasive contrast enhancing mass: it is likely that it is a 
lymphoma in the case that the mass captures the contrast in a homogeneous and non-
homogeneous form or with the presence of a ring of glioblastoma for the absence of central 
necrosis (except for patients with AIDS). Microscopically, lymphoma consistsof irregular 
angiocentrichypercellularity, with marked reactive gliosis, apoptosis, and lack of microvascular 
proliferation; it is composed of not cohesive, round, or reniform cells with poor cytoplasm, 
vesicular nuclei, with evident chromatin and nucleoli. 
Diffusion and metastasis 
Infiltrating growth is one of the fundamental aspects for the definition of diffuse gliomas and, 
above all, glioblastoma is characterized by a rapid invasion of adjacent brain structures. 
Generally, the tumor moves along the white matter, although it is not uncommon to involve the 
cortex or deep gray matter: when the growth follows the callous body, and then extends into the 
contralateral hemisphere, a symmetric lesion is formed and it is defined as "butterfly 
glioblastoma". Likewise, the tumor may spread through the fornix, the anterior commissure or 
the optical radiations, resulting in perivascular aggregates, subpial dissemination and 
perineuronalsatellitosis, which form Scherer's secondary structures. 
Infiltration tends to extend with a decreasing gradient of cell density starting from the center of 
the tumor, and it is possible to identify,by microscopy, single cell that stands even several 
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centimeters from the major lesion, both in hyperintense regions in T2 to RM and in regions that 
appear not to be involved by the disease in imaging: these cells are often the starting point of a 
recurrence after therapy, either because they escape the targeted resection and radiotherapy, or 
because they are located in regions where the haematopoietic barrier remains intact and thus 
reducing the bioavailability of drugs; it seems, however, that the activation of a transcriptional 
migration program is associated with a proliferation reduction. 
Many glioblastomas at the onset may exhibit a typical growth pattern of gliomatosiscerebri 
which, despite being deleted as a clinical entity by the WHO 2016 classification, is still 
considered a typical growth variant of diffuse gliomas, with frankly neoplastic and aggressive 
astrocytomas inside intact brain areas that may be within the same hemisphere (with 
involvement of at least three lobes) or both cerebral hemispheres until reaching the deep gray 
matter, the brainstem, the cerebellum and the spinal cord. 
Mechanisms underlying the invasiveness of glioblastomas involve cellular motility, cell-cell and 
cell-matrix interactions, and extracellular matrix remodeling. In fact, tumor cells are able to 
secrete invasion-promoting proteolytic enzymes such as the MMP2 and MMP9 matrix 
metalloproteinases, uPA and its uPAR receptor, and catepsins, as well as integrin receptors that 
mediate interaction with molecules of extracellular space, causing changes in the cytoskeleton 
and activation of intracellular signaling pathways such as AKT, mTOR and MAPK; in this regard, 
the existence of "adaptive proteins", including Pinch, has been shown to catalyze these 
interactions by providing all of the protein structures in the directions in which the contact is 
most likely to occur, thus accelerating the processes of signal transduction. 
Migration is also favored by growth factors expressed by glioblastoma cells, including hepatic, 
fibroblastic, epidermal and endothelial growth factors; cells with EGFR amplification are usually 
located at the apex of the infiltrated portions, suggesting a key role in peripheral expansion. 
Tumor expansion moves radially from the center of the lesion, that is necrotic and hypoxic, and 
hypoxia activating factors such as HIF1-alpha helps this migration: hypoxic cells show an 
increase in intracellular protein associated with motility and greater interaction with the 
extracellular matrix. In terms of motility, it is essential that cells adhere to the stroma and carry 
the entire body of the cell: this movement is guaranteed by prolongations called "filopods", 
highly augmented in the tumors, which increase the ability to adhere and drag the cell body; 
fascin protein is involved in this process, inducing the formation of actin filaments within these 
cellular protrusions, so as to make these prolongations more robust. 
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Despite this rapid infiltrating growth, however, glioblastoma rarely invades the subarachnoidal 
space or spreads through the liquor; similarly, rare is the invasion of the dura, the veins and the 
bone. At vascular level, tumor cells tend to adhere around the vessels, without entering them. 
Recently, however, cancer cells circulating in the blood have been identified, unable to give 
metastasis because of the optimal immune system and because of themicroenvironment 
ofdistant organs that is inadequate and can inhibit cell growth and implant.Extracranial cancer 
detection is unusual in patients who did not have surgery. 
Prognosis and Therapy 
Glioblastoma is atumor with poor prognosis: most patients die within 15 to 18 months of 
diagnosis, less than 5% survive to five years. 
Young age (<50 years) and complete macroscopic resection of the tumor are associated with 
longer survival, as well as MGMT promoter methylation and IDH mutation. 
About the age, several trials have shown that younger patients show longer survival, also 
because of a wider therapeutic choice than in elderly subjects, where it is greatly influenced by 
potential comorbidities; to date, however, it is not possible to identify a valid cut-off to guide the 
clinical-therapeutic choice. 
MGMT promoter methylation is a key predictor of efficacy and response to alkylation: up to 90% 
of long-surviving patients have a mutation in this regard; it is interesting to note how the 
percentage of mutations is not influenced by age. 
IDH1 and IDH2 mutations, albeit associated with secondary glioblastoma, are positive 
prognostic factors; uncertain is the role of p53 mutation, which in some studies resulted to be 
correlated with increased survival, whereas in others it did not show any prognostic 
significance; the correlation between EGFR amplification and survival is demonstrated (it is 
hypothesized that it may be prognostically unfavorable only if associated with p53 wild-type). 
Some studies have associated the loss of long arm of chromosome 10 to a lesser survival, while 
the correlation between PTEN mutation and prognosis is unclear. 
Histologically, the microscopic aspect of the tumor typically does not give any significant 
prognostic implications: an exception, still to be validated, would be for giant cell glioblastoma, 
correlated with a better prognosis than other forms of glioblastoma, especially if considered as a 
regressive form.  
A significant tribute to poor prognosis of glioblastoma is high resistance to standard therapy 
that provide a slightincrease of survival despite aggressive tumor resection, and that consists of 
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temozolomide chemotherapy, focal radiotherapy (with maximum dose directed to the region of 
contrast enhancing in MRI) and subsequent adjuvant chemotherapy at the maximum tolerated 
dose. This resistance is determined by a number of factors, including the presence of a blood-
brain barrier, that can significantly reduce the bioavailability of drugs at the brain, along with 
high interstitial pressure in tumor tissue that contrasts drugs diffusion. 
Besides this, there is tendency to invasion by cancer cells, that can thus spread at distance inside 
the CNS, remaining within the hemato-encephalic barrier and being consequently protected; the 
persistence of DNA repair mechanisms (such as mismatchrepair or excisionrepair base) that 
reduce the effectiveness of radiotherapy and chemotherapy; intratumoral heterogeneity and 
genetic instability that hesitate in populations of cells resistant to multiple therapeutic 
approaches; the presence of a stem-like cell compartment potentially retaining resistance 
mechanisms other than those of the remaining tumor mass and which may contribute to 
therapeutic failure; genetic alterations caused by the therapeutic treatment itself or by tumor 
progression. 
Molecular alterations are responsible for specific mechanisms of resistance or susceptibility: 
p53 inactivation causes defects of apoptosis, as well as mutations of the protein associated with 
retinoblastoma Rb1 result in an ineffective cell cycle arrest. RAS point mutations, albeit rare in 
glioblastoma, are critical because RAS mediated signaling pathways are activated by EGFR, 
PDGFR, and by IGF1 insulin-like growth factor receptor. Downstream mutations, such as a 
silencing of the oncosoppressorNF1 gene, may trigger the RAS pathway, causing an unregulated 
cell proliferation. 
Similarly, abnormal activation of PDGF, IGF1 and epidermal growth factor signaling pathways, as 
well as alterations downstream to PTEN gene, may activate the PI3K circuit. Knowledge of these 
anomalies, coupled with the complete identification of all genetic changes in glioblastoma 
progression, has proved to be crucial to hypothesize a targeted therapeutic approach using a 
single signaling inhibitor. 
The recent identification of a stem-like cell population has added new difficulties in treating this 
tumor, as these highly tumorigenic cells in immunodepressive mice are capable of overcoming 
the classic therapeutic schemes: the addition to therapy of bevacizumab anti-VEGF antibody has, 
however, presented an encouraging response rate in 65% of cases. An additional problem for 
this cell population is given by the radio-resistance mechanisms, with the activation of DNA 
damage repair that is greater than the surrounding tumor mass.Thus, resistance of 
glioblastomas to therapy is partially dependent on stem cell compartment on which the radio-
chemotherapy combined approach is failing and consequently the cells, remaining vital, can lead 
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to recurrence. Promising results in this regard are from the study of bone morphogenetic 
protein 4 (BMP4): in vitro, this factor is able to block the proliferation of CD133-positive cells, 
and in vivo it can reduce tumor growth, thus acting as a negative regulator; it is assumed to be 
employed in association with the standard therapeutic approach. 
Radiotherapy in many cases may delay the enlargement of glioblastoma, resulting in a transient 
phase of quiescence or remission, as evidenced by the stability or regression of neurological 
deficits, and by the reduction of the MRI contrast enhancing mass; in some patients, however, 
the tumor progresses without being affected by the treatment.  
The tumor, after radiotherapy, shows low cellularity, with abundant pleomorphic astrocytes that 
can be both normal  and cancer cells with atypia induced by radiotherapy; sometimes there are 
small cells with hyperchromic nuclei and poor cytoplasm whose meaning is unknown. The 
surrounding cerebral parenchyma, after irradiation of the tumor, shows foci of coagulative 
necrosis that can be distinguished from tumor necrosis using PET with fluorescence-glucose: 
tumor necrosis, in fact, is metabolically active or "hot", while radionecrosis has no metabolic 
activity ("cold"); it is also possible to identify fibrinogenic necrosis and vascular thickening that, 
when present in the tumor site, represent the desired and desirable effect of the therapy. 
A sample of irradiated brain tissue can therefore present reactive gliosis, radio-induced necrosis, 
quiescent or active tumor areas: if there is evidence of mitotic activity, it can be concluded that 
the cellular population is in a quiescent phase of growth; if, on the contrary, there is a high Ki-67 
proliferation index associated with necrosis, pseudopalisading, and microvascular proliferation, 
then the lesion may be both active, and therefore not responsive to therapy, and re-activated. 
 
1.3 Glioblastoma IDH-mutated 
Epidemiology and clinical features 
IDH-mutated glioblastoma is defined as a high grade glioma with predominant astrocytic 
differentiation characterized by nuclear atypia, cell pleomorphism, high mitotic activity, 
widespread growth pattern with microvascular proliferation and/or necrosis, in the presence of 
IDH1 or IDH2 genes mutations. It is also called secondary glioblastoma [4]. 
It accounts for about 10% of all glioblastomas, with onset in younger patients (44 years) than 
those diagnosed with primary glioblastoma (62 years); male/female ratio is significantly lower 
than that seen for primary glioblastoma, equal to 1.05: 1 versus 1.42: 1. Different is also the 
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duration of clinical history, equal to 30 months in IDH-mutated forms and less than 15 months in 
IDH-wildtype forms. 
In contrast to IDH-wild type glioblastoma, which has a diffuse distribution along the anatomic 
pathways, secondary IDH mutated variant shows predominant involvement of the frontal lobe, 
particularly of the region surrounding the rostral extension of the lateral ventricles; this location 
reflects the preferred location for example of the diffused IDH-mutated WHO II astrocytoma, 
supporting the hypothesis that there is an evolution from a low grade lesion. 
Genetic profile 
The fundamental and characteristic genetic characteristics of secondary glioblastoma are IDH 
mutations associated with a hypermethylated phenotype, alterations already identifiable in low 
grade lesion, along with TP53 and ATRX mutations and long arm loss of chromosome 10. 
IDH mutations were first described in 2008 as those "mutations in most young patients with 
secondary glioblastoma associated with an increase in overall survival". It is therefore possible 
to consider these mutations as a molecular diagnostic marker and at the same time prognostic, 
fundamental in the characterization of the glioblastoma variant. 
The most common IDH1 mutation is R132H (CGT → CAT), found in 91% of cases, followed by 
rarer mutations such as R132C (CGT → TGT, 3.6-4.6% of cases), R132G (0, 6-3.8%), R132S (0.8-
2.5%) and R132L (0.5-4.4%). IDH2 gene codifies for the only human protein that is homologous 
to IDH1, which uses NADP+ as an electron acceptor; IDH2 mutations are rare and localized on 
residual R172 (R172K), which is the analogue of IDH1 R132 residual, located in the active site of 
the enzyme, where it forms hydrogen bonds with the isocitrate, representing its substrate. 
Based on these considerations, a glioblastoma to be defined as IDH-mutated should be tested by 
searching for IDH1 mutation R132H and other IDH1 mutations on codon 132 and IDH2 on codon 
172; in clinical practice, however, it is often sufficient the immunohistochemical evaluation 
ofR132 codon in the search for the most frequent mutation, R132H, using an antibody that is 
addressed to the gene product: if mutation is present, it is referred to as IDH-mutated form. It 
has been shown that, in the absence of an IDH1 R132H mutation, the probability of an 
alternative IDH mutation is less than 1% in patients over 54 years of age. In this case, in absence 
of IDH1 immunoreactivity, a diagnosis of IDH- wild type glioblastoma can be performed.   
Over 90% of IDH mutated glioblastomas exhibit a proneuralmolecular expression profile, and 
about 30% of glioblastomas classified as proneural have been shown to be IDH-mutated. 
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Conversely, IDH-wild-type glioblastomas exhibit significant variability in molecular expression 
patterns. 
A fundamental difference between the two categories of glioblastomas seems to be related to the 
origin cells: in addition to the presence/absence of IDH mutations, the difference in age and sex 
of onset, together with the different localization within the brain structure, suggests that 
wildtype glioblastoma cells of origin have a greater tendency to disseminate than those of the 
IDH mutated variant that instead tend to originate or migrate to the frontal region; recent 
studies have also shown that CD133 expression is higher in primary glioblastoma cells and 
associated with the formation of neurospheres only in IDH-wild type tumor forms. 
Prognosis 
Already in 1940, H.J. Scherer, a pioneer in the field of glioblastoma research, stated that "from a 
biological and clinical standpoint, a secondary glioblastoma that originates from a low grade 
lesion should be distinguished from a primary tumor and presumably represents what is in the 
literature defined as a glioblastoma with a long clinical history " . This observation was 
confirmed by subsequent studies in which the different duration of clinical history in the two 
forms (4 months versus 15 months) was highlighted, in addition to the different outcomes in 
terms of therapeutic approach: a combined approach with radiotherapy and surgery, in fact, 
guarantees a survival of 9.9 months in primary and 24 months in secondary variants; if adjuvant 
treatment with chemotherapy is also added, it reaches 15 months in primary and 31 months in 
secondary. 
 
 
1.4 Glioblastoma NOS 
NOS (not otherwise specified) glioblastoma is defined as a high grade glioma with a 
predominant astrocytic differentiation characterized by nuclear atypia, cell pleomorphism, high 
mitotic activity, widespread growth pattern with microvascular proliferation and/or necrosis, 
without determination of the status of genetic mutations IDH1 or IDH2. 
1.5 Oligodendroglioma,  IDH-mutant and 1p / 19q-codeleted and oligodendroglioma, NOS 
The diagnosis of oligodendroglioma and anaplastic oligodendroglioma requires demonstration 
of both IDH gene family mutation and the combined loss of the entire chromosomal arms 1p and 
19q (coding 1p / 19q). In the absence of immunohistochemical positivity for the R132H 
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mutation of the IDH1 gene, it is recommended sequencing the codon 132 of the IDH1 gene and 
codon 172 of the IDH2 gene. In case of non-availability of these tests or in a context of 
inconclusive genetic results, a histologically typical oligodendroglioma form should be named 
NOS. In case of anaplastic oligodendroglioma,if  genetic diagnostic results are absent, the 
presence of genetic features that are typical of glioblastoma must be excluded [4]. 
Oligodendroglioma cells (Figure 3) typically show round, regular and monotone nuclei with a 
well-defined nuclear membrane and a very slight cellular variability. The cytoplasm tends to 
bulge during formalin fixation and paraffin inclusions, giving rise to cells with well-defined cell 
membranes, clarification of the cytoplasm and a central spherical nucleus, a combination of 
factors that give rise to the classic "fried egg-like” appearance. 
 
 
 
 
 
 
 
 
 
 
2. PATZ1 
PATZ1 (POZ/BTB and AT-hook-containing zinc finger protein 1), also known as ZNF278 (zinc 
finger protein 278), MAZR (MAZ-related factor) or ZSG (zinc finger sarcoma gene),is a 
"presumed" transcription regulator, composed of 7 zinc finger domains (Cys2-His2 type). PATZ1 
gene codes for 4 alternative proteins (from 53 to 687-amino acids long) and maps to 
chromosome 22q12 [8]. 
The knowledge of factors that are implicated in the regulation of gene expression that takes 
place according to a mechanism that is time-and tissue-specific, is still now subject  to scientific 
fervor. Transcription factors have a prominent role and, as modulating proteins, they may  be 
Figure 3.  Oligodendroglioma: morphologic features 
Grade II: a. delicate "chicken-wire" network of branching capillaries; b. typical "fried egg" pattern of 
cytoplasm; 
Grade III: c. evident mitotic activity; d. ipercellularity. 
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classified according to the structure of their DNA-binding domain. One of these is the zinc finger 
domain, so named because of its link to the zinc, and of its likeness with Kruppel protein, a 
protein of segmentation in Drosophila.It is 25-30 amino acids long and it represents one of the 
commonest form of DNA-binding proteins [9]. 
Broad Complex, Tramtrack and Bric à brac (BTB) domain, also known as Poxviruses and Zinc 
finger (POZ), is a protein-protein interaction domain, which has been preserved in evolution. 
Originally, the members of POZ family were all transcriptional repressors, with a role in the 
embryological development of Drosophila.Broad Complex factors are essential for 
metamorphosis of Drosophilaand their mutations cause severe impairment of the central 
nervous system after hormonal stimulation [10,11]; Tramtrack is a key regulator in the ocular 
development and the ablation of one or both ttk isoforms  causes ocular alterations; finally, Bric 
à brac(Bab) rules the morphogenesis of the ovaries and the limbs [12]. All these findings 
involving the Drosophila have been the starting point for the search of  a developmental role of 
POZ factors also in vertebrates.  
Peculiar featuresof PATZ1 protein is the concomitant presence of POZ domain at N-terminal end, 
AT-hook domain in the center, and 4-7 zinc finger C2H2 domains at the C-terminal end 
(Figure4).  
2.1 Role in embryology 
The role of PATZ1 in embryonic development has been investigated in mice. Using experiments 
on "null" embryos for PATZ1, which is rendered naked for expression of PATZ1, a normal mouse 
embryo was compared. The group of Fedele [13] followed the embryos with in situ 
hybridization, between 8.5 and 17.5 days post coitum (dpc), during which the most critical 
phases of organogenesis take place. In general, the expression of PATZ1 is ubiquitous in the 
early stages of development and becomes much narrower in the later phases. The expression of 
this protein is much stronger in the central nervous system until it is confined in the final stages, 
predominantly to the proliferating neuroblasts of the periventricular areas, but also in the 
telencephalus (cortical plate, hippocampus, striatal neuroepithelium and the subventricular area 
). In the intermediate gestation phase, a strong expression was observed at the level of the 
olfactory and respiratory epithelium of the nasal cavities, in the retina, in the Rathke’s cleft cyst, 
thymus, thyroid, salivary glands and dental precursors. 
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In mice with homozygous mutation, it was observed a slight growth delay (the mean body 
weight was 10-20% less than wt mice) for gestational age and esencephaly in a percentage of 
cases. Esencephaly is a neural tube defect caused by deficient closure of neural folds during 
neurulization; where this defect is not present, however, other cerebral abnormalities are 
observed in homozygous mutants: the whole encephalus is smaller, the ventricular system  is 
larger, periventricular structures are thinner, particularly at the level of thetelencephalus and 
diencephalusandchoroid plexus of the IV ventricle is hypoplasic. 
Homozygous mutation is, in a large percentage of cases, lethal: from the mating of heterozygous 
mice, the percentage of living homozygous mice recorded by experiments is 4% versus 25% 
expected. Many of the deaths of these embryos are to be attributed to outbreaks of cardiac 
output defects. The prevalent expression of PATZ1 in the mesencephalus had already been 
observed in previously published data [14], as well as its membership of a group of candidate 
genes susceptible to alcoholic fetal syndrome, characterized by defects in the development of the 
central nervous system [15]. 
PATZ1 also has a critical role in spermatogenesis [16], in fact, it was seen that male null mice (- ;-
) were infertile: the testis of these mice hadsmaller weight and size than the average. 
Figure 4.  Structure of PATZ1 protein 
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Histological examination revealed the presence of semen tubules with a lower diameter and 
characterized by an interstitial tissue growth, containing hyperplastic Leydig cells. The most 
characteristic aspect to be observed was the blockage of spermatogenesis; most ofthetubules 
appearedcystically dilated, with loss of cellular component. Many tubules, in fact, contained only 
Sertoli cells and few spermatogons, other contained Sertoli cells, spermatogons in degeneration, 
and rare spermatocytes. Infertility was to be attributed to the absence of spermatids and 
spermatozoa. In association with impaired spermatogenensis, an increase of apoptosis was 
observed, resulting in a loss of tubular structures. 
Expression analysis of PATZ1 in the normal testicle, using Northern blot, western blot and 
immunohistochemical techniques, revealed its presence in Sertoli cells, in a few Leydig cells and, 
among germ cells, exclusively in spermatogons. 
The expression of PATZ1 was also studied, using total RNA in wild-type mice at different ages 
and it was seen to be maximum at 6 days when the germ cell count is rich in spermatogenes, still 
present at 13 days when spermatocytes are observed, and it is very low at 34 days when 
spermatocytes and spermatids are present. 
All of these observations lead to the conclusion that PATZ1 protein plays an important role in 
the development of the testicle, by attenuating the activity of the androgenic co-regulator RNF4. 
Although it is unclear whether AR is expressed in germ cells, spermatogenesis is essentially 
dependent on androgen action, of which Sertoli's cells may be the source. Another important 
observation is that PATZ1 is expressed essentially by spermatogons, where it plays a role in 
repressing the transcription, in order to maintain stem cell pool. 
2.2 Role in cancer 
The first description of the association between PATZ1 and cancer dates back to 2000, when an 
Italian group [17] identified, in the small cell tumors, the existence of fusion between EWS and a 
new gene coding for a zinc finger (ZSG , Zinc finger Sarcoma Gene). It is well known that the 
family of cancers to which belongs Ewing's sarcoma and small cell tumors, is often carrier of 
translocation between the EWS gene, mapping on chromosome 22 (22q12), and different types 
of genes, mapping on different chromosomes and encoding DNA binding proteins (FLI1, ERG, 
ETV1, etc.), giving rise to tumors with distinct phenotypes (clear cell sarcomas, small cell 
desmoplastic tumors, mixoidliposarcoma, etc.). The EWS gene is, by definition, a "promiscuous 
partner". The peculiarity of the discovery was that the gene of the "zinc finger" protein identified 
in this study, subsequently better encoded and named PATZ1, mapped precisely on Chr22q12: 
for the first time it was described an intra-chromosomic rearrangement not detectable by 
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cytogenetic techniques, activating the EWS gene, in a case of Ewing's sarcoma,with t(1; 22) 
(q36.1; q12) type translocation. 
The rearrangement concerns EWS intron8 and ZSG exon1, by creating a chimeric sequence 
containing the fusion between the EWS transactivation domain and ZSG zinc finger domain. The 
latter, therefore, lacking the transcriptional repressor domain at the N-terminal end (POZ 
domain), becomes an activator, responsible, probably, of neoplastic stimulation. The close 
resemblance of this protein with other proteins of the same family, with oncogenic function 
(PLZF, involved in acute promielocytic leukemia and BCL6, in non-Hodgkin's large B cell 
lymphomas), encouraged the search for its possible role in cancerogenesis. 
Another oncological field where PATZ1 action has been explored is that of the glioma. 
Experiments were doneon [18] glioma cell cultures expressing PATZ1 mRNA, which were 
resistant to apoptosis induced by Fas-L, and an increase in apoptosis induced by FasL after 
stimulation with actinomycin D was observed. Apoptosis is an active cell death process, 
operating under normal and pathological conditions and it may be induced by a large number of 
unrelated stimuli. Fas (CD95) and its ligand (FasL) are members of the TNF receptor family and 
their binding triggers the death of cells expressing the receptor. Many neoplastic cells, including 
those of glioma, express these proteins and can be resistant to death induced by this link [19-
21]. It is also known that FasL expression is a mechanism by which neoplastic cells escape 
immunosurveillance. 
Several mechanisms are described through which glioma cells resist Fas-induced death [22,23]. 
Characterized by great genetic instability, glioma cells, through genetic and epigenetic 
alterations, are able to choose between different mechanisms of resistance, (severe "mutant 
phenotype")[24]. 
PATZ1 mRNA is expressed in brain tissue, without any differences between normal and tumor 
and, as mentioned above, although not implicated directly in the molecular cascade of apoptosis, 
the testis seems to play an important role in spermatogenesis: its shutdown causes an increase 
in apoptotic activity within semen tubules. 
Similarly, in glioma cells, PATZ1 gene has been down-regulated by the use of a specific siRNA 
(small interfering RNA or silencing RNA, a RNA molecule with a length of 19-21 nucleotides, 
with the function of inhibiting the expression of individual genes), and it was observed that in 
cultures with resistance to apoptosis induced by FasL, there was an increase in cells in apoptosis 
and a reduction in the percentage of vital cells. PATZ1 down regulation would also increase the 
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sensitivity of glioma cells to apoptosis induced by mechanisms other than Fas (TRAIL, whose 
receptor is DR5). 
The final effect of PATZ1 on cellular lines of glioma is therefore the increase of apoptosis and the 
reduction of proliferative activity;these results are encouraging for the detection of a specific 
siRNAdirected to PATZ1 as a therapeutic agent for the treatment of gliomas. 
As for the testicle, the same working group [16] that evaluated the protein's 
immunohistochemical expression in normal tissue also did it in samples from testicular germ 
cell tumors, of both seminomatous and non-seminomatous type. In particular, it was observed 
that PATZ1 expression is greater in the cytoplasm rather than in the nucleus in both tumor 
types; moreover, all in situ carcinomas expressed the protein. These results, that were 
confirmed by western blot analysis, were in contrast to what was known until then. Since PATZ1 
belongs to a family of repressor factors, it has been suggested to include it among proteins with 
oncosoppressor role. In testicular tumors, this observation proved to be ineffective if we 
consider that the protein is hyperexpressed, but still valid if we consider that in these tumors it 
is delocalized in the cytoplasm. 
At the same time, it was argued that the cytoplasmic sequestration of nuclear proteins is a 
mechanism through which cancer cells promote carcinogenicity in human [24,25]. As a result, a 
question was unanswered: does cytoplasmic delocalization contribute to the abolition of its 
original function (repression) or to the acquisition of a new function in the cytoplasm? 
Extremely alien to the previously acquired knowledge, it is the study of the role of PATZ1 in 
colon cancer. The  transcriptional level of the protein was evaluated [26]via RT-PCR, finding an 
increase in tumor samplescompared to normal tissue. To study the function of "zinc finger" 
protein in this category of carcinoma, a cell line of colorectal carcinoma, with PATZ1 over-
expression, was created and then transfected with siRNA directed against PATZ1. Down-
regulation of this gene resulted in a decline of growth and proliferation, suggesting a possible 
role of proto-oncogenes for this protein. 
PATZ1 expression and function in thyroid cancer [27] was analyzed, identifying a potential 
oncosoppressorrole, mainly involved in the inhibition of epithelium-mesenchyma transition and 
in cell migration. In fact, the immunohistochemical expression is reduced in tumor tissue 
compared to normal, with differences in intensity: slightly higher in well-differentiated cancers, 
reduced or even absent in poorly differentiated and anaplastic forms. It was observed, in poorly 
differentiated and anaplastic forms, a particular trend of the protein to delocalize from the 
nucleus to the cytoplasm. These observations could lead to thinking at the loss of PATZ1 and its 
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cytoplasmic location as a possible indicator of an undifferentiated, mesenchymal, and more 
aggressive phenotype. 
In thyroid cancer, PATZ1 expression seems to start up p53 pathway that is implicated in the 
blockade of epithelium-mesenchymal transition through the down regulation of some genes 
(such as EpCAM, a stabilizing molecule inhibitor intercellular junctions , such as E-caderine, or 
through the direct inhibition of adhesion membrane components such as fibronectin) or the up 
regulation of actinic dynamics (RhoE and NOTCH). This effect is also observed when p53 gene is 
mutated. 
From these evidence, it is apparent that PATZ1 is a protein whose role in cancer is not well-
defined: it may play both as oncoppressor and as oncogene. The reason why this protein has 
great versatility is unknown, as well as its mechanism of action. 
As with all members of the POK protein family, transcriptional activity is dependent on the 
formation of oligomers, mediated by the POZ domain, conferring a role of architectural 
transcription factor, rather than typical transcriptional actor, acting as repressor or activator, 
depending on the partner. In fact, for PATZ1 it has been observed a role of activator or repressor 
of c-myc, of activator of  mast cell protease 6 and of FGF4, and of repressor of androgen receptor 
gene, CD8 and BCL6.  
PATZ1 gene maps to chromosome 22 where is also the fragile site of FRA22B, affected by 
heterozygosity loss, that is typical of several solid tumors, thus supporting an onco suppressor 
role for this protein. Moreover, both homozygous and heterozygous knockout mice may 
spontaneously develop several tumors, such as non-Hodgkin BCL6 (+) lymphomas, sarcomas, 
and hepatocellular carcinomas. On the other hand, in some malignant neoplasms (colon, testicle 
and breast) an over-expression of PATZ1 has been observed, as it was seen that a down-
regulation of the gene may block colon cancer growth and increase the sensitivity of gliomas to 
apoptotic stimuli. 
2.3 Role in stemness 
In normal tissues, cells are organized hierarchically. At the apex of the pyramid there is a stem 
cell that originates two “daughter cells”, a stem cell and a cell that will start a differentiation 
program; that cellular division is therefore defined asymmetric (127). Cells that lost their 
staminality status are defined as progenitor cells (or also transit-amplifying cells) and, present 
in many normal tissues, they represent intermediate forms between stem cells and their fully 
differentiated descending cells that have terminated their cycles growth and division (128). 
Consequently, progenitor cells can produce dozens, if not hundreds of progeny that are 
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differentiated from a single division of the original stem cell; stem cells may therefore rarely 
replicate, even in tissues that have a continuous cell replacement (intestinal mucosa, for 
example). 
The same replicative pattern [28] also applies to tumor tissues, whose progenitor is the 
CancerStem Cell (CSC) cell, capable of self-regenerating and of producing numerous neoplastic 
progenitor cells that constitute the tumor. Although stem cell and progenitor cell are genetically 
identical, the latter, having lost its ability to self-regenerate, it has lost the ability to regenerate 
the tumor. Tumor stem cell shares the same environmentwith the normal counterpart, 
continuously fed by the presence of autocrine signals [29]. 
Although tumor stem cells represent the minority of the cellular population that makes up a 
tumor, they are responsible for tumor conservation and progression as well as the ability of the 
tumor to reproduce in xenograft murine models. Murine experiments have shown that depletion 
of tumor stem cells makes difficult to generate the tumor in xenograft transplantation and 
prolongs the survival of tumor carriers [30-32]. While the feasibility of using tumor brain stem 
cells as potential therapeutic targets in glioblastomas has recently been validated in vivo (134), 
the biological mechanism that is at the basis of their functioning is unknown. 
The relationship between PATZ1 and staminality is subject to continuous research stimulated by 
various evidences. Recently, PATZ1 [33] has been shown to act as a pluripotency regulator in 
embryonic stem cells (ESCs), directly implicated in the control of pluripotency master gene, such 
as Pou5f1 and Nanog which, together with Sox2, are needed for self-immune and pluripotency of 
ESCs. 
Embryonic stem cells are obtained from in vitro culture of cells extracted from the blastocyst's 
inner cell mass (IMC, Inner Cell Mass), in the pre-implantation phase [34,35]. These are cells 
characterized by two fundamental properties, the ability ofself-keeping, or to stay in a 
proliferative state  for a long time, and of pluripotency, or the ability to differentiate into 
different types of specialized cells. ESCs may self-generate, by the action, in the culture medium, 
of leukemia inhibitor factor (LIF, belonging to the cytokine family of IL6 and acting through the 
activation of the Stat3 gene) and bone morphogenetic protein 4 (Bmp4) in the rat [36,37], and 
the basal fibroblast growth factor (bFGF) and the transforming growth factor β (TGFβ) in 
humans [38,39]. Although there are differences between murine form and human form of ESCs, 
the factors (Oct4, Sox2, Klf4 and c-Myc) that are responsible for maintaining a state of 
indifferentation of embryonic stem cells are the same in humans and in mouse.Pluripotency 
factors, known as the Yamanaka factors [40], have many target genes (thousands of orders) and 
are implicated in numerous pathways (development, metabolism, cancer, etc). Oct4, Sox2 and 
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Klf4 can also self-regulate, unlike c-myc. Their mechanism of action is not clear and often the 
interconnection between the different pathways may occur. 
Oct4 (Octamer binding transcription factor 4, binding nucleotide octamer ATTTGCAT), also 
known as POU5f1 (POU domain, class 5, transcription factor 1) is present in embryonic tissues at 
different concentrations: high in the hypoblast, intermediate in the internal cell mass and low in 
the trophoectoderm. Demethylation of DNA is essential for its transcription. Oct4 forms a 
trimeric complex with Sox2 and is highly expressed in the developing brain, locating mainly in 
specific cellular layers of the cortex, hippocampus, olfactory bulbs, and cerebellum. 
Sox2 (SRY, SexdeterminingRegion Y-box2) is an essential transcription factor in the self-
maintenance of embryonic and neural stem cells. In neurogenesis, Sox2 is expressed 
developmental cells of the neural tube, as well as in proliferating progenitors of the central 
nervous system. It is down-regulated at the end of the cell cycle of progenitor cells, when these 
become post-mitotic cells. Cells expressing Sox2 are both self-regenerating and differentiating 
neuronal cells. Sox2, along with Oct4, binds Nanog promoter, regulating the expression of 
downstream genes implicated in self-maintaining ESCs. 
KLf4 (Kruppel-likefactor) is a factor that belongs to the family of proteins with "zinc finger" 
domain, whose peculiarity is the presence, at the C-terminal end, of 2 highly conserved C2H2 
domains, containing a zinc finger pattern. It is a fast response mediator to signals triggered by 
LIF-Stat3 and directly links Nanog's promoter to help Oct4 and Sox2 to regulate Nanog's 
expression. 
c-Myc, carries out numerous cellular functions and is involved in many biological pathways, 
including the control of self-regeneration in embryonic stem cells. Mapping the target genes of 
these factors suggested that its role in maintaining pluripotency of ESCs should be different from 
the so-called "core" factors (Nanog, Sox2, and Oct4). c-Myc has many more target genes than 
other "core" factors and it is mostly involved in pathways associated with metabolism and 
protein synthesis, rather than in pathways related to development. 
By gene expression analysis in cells of the Inner Cell Mass in the blastocists of the mouse, it has 
been observed that PATZ1 is much more expressed than in non-pluripotent 
trophoectoderm[41], as well as in Oct4 + cells compared to Oct4- [42]. Furthermore, the 
genomic region of PATZ1 represents the binding site of important factors (Oct4, Sox2, Nanog, 
Klf4 and c-Myc) [43,44]. PATZ1, in turn, is able to control the expression level of pluripotency 
genes, such as Nanog and Pou5F1, and its knockdown is able to determine, in murine models, 
the differentiation of ESC cells [45]: we have seen , in fact, by PATZ1 shutdown, that there is an 
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increase in the expression of markers of the trophoectoderm, endoderm and mesoderm and a 
reduced expression of pluripotency genes (confirmed by immunoblot techniques and gene 
expression analysis in microarrays). It has been identified in the CR4 region, the exact binding 
site of PATZ1 on the promoter of the Pou5f1 gene, which is in turn bound to other factors (148, 
149, 150) such as Nanog and Oct4; it is also known that PATZ1 binds the proximal promoter of 
Nanog gene. Gene mapping techniques have highlighted the binding sites of PATZ1 factor in 
numerous genes, which in turn have been subjected to genetic ontology studies from which it is 
apparent that these genes are involved mainly in embryonic development but also in cellular 
proliferation, metabolism, and apoptosis. Many of PATZ1 binding sites are often shared with 
pluripotency transcription factors, though not belonging to the core of pluripotency factors or 
the c-Myc family. The important role of PATZ1 in regulating mouse embryonic stem cells has not 
yet been proven in human counterparts, but being the transcriptional network similar in the two 
species, it is very likely that it will be demonstrated.Undoubtedly, it is of great interest that, at 
the final stage of the development of mouse embryos, the expression of PATZ1 protein is 
confined to districts that host proliferating neural stem cells [46]. 
Studies on the testicle [47,48] demonstrated that POK protein family Plzf, regulates the 
mechanism required for the self-regeneration of spermatogenesis stem cells, interacting with 
Oct4 transcription factor; moreover, all the morphological alterations observed in the testes of 
Plzf-null mice are the same as those observed in PATZ1-null mice, demonstrating that PATZ1 
probably also plays a role in testicular stenitis.Recently, it has been shown that pluripotent state 
can be generated by somatic mouse cells through the ectopic expression of Yamanaka 
transcription factors [40] (Oct4, Sox2, Klf4 and c-Myc). Induced pluripotent stem cells (iPSCs) 
resemble embryonic stem cells, also having the ability to self-sustain pluripotency and 
differentiate into many cell types. The exact mechanism of induction of pluripotency has not 
been well understood, but it undoubtedly represents a great possibility with extensive potentials 
for application in regenerative medicine. There are "barriers" that the somatic cell needs to 
overcome in order to be reprogrammed in a pluripotent stem cell. The reprogramming process 
is a dynamic process that involves a cascade of cellular events such as gene mutations 
responsible for differentiation along a specific line, pluripotency gene re-activation, 
mesenchyma-epithelial transition (MET), cellular senescence overcoming , acquisition of cellular 
immortality, re-activation of chromosome X and reset of chromatin signature.Cell senescence 
appears to be a limiting factor for reprogramming at the initial stage. The locus of the 
oncosoppressor Ink4a / Arf plays a critical role in regulating senescence in many types of cells. 
For example, silencing Ink4a / Arf locus or the ablation of its activator Jmjd3 seems to reduce 
cellular senescence and significantly improve the efficiency of reprogramming. 
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The change of the epigenetic panorama represents another barrier mechanism for 
reprogramming. Pluripotent cells possess a highly plastic chromatin structure because they are 
globally open and decondensed with a high ratio between the active and the repressed form. In 
order to successfully complete the reprogramming process of somatic cells in which chromatin 
is predominantly condensed, it is necessary to make possible the conversion into open form, 
thus accessible to the action of the transcription factors. In fact, inhibition of chromatin 
condensation, ablation of the NuRD / Mbd3 repression complex, inhibition of HDAC or H3K4me3 
activity strongly increases the induction of iPSCs [49]. The mechanism by which epigenetic 
factors have an impact in the reprogramming process is not well known. 
In this regard, we have investigated the role of PATZ1, as this is a transcription factor that 
operates differently, depending on the cellular context and being implicated in maintaining the 
pluripotency status in ESCs. 
It has been seen that PATZ1 hyper-expression inhibits the reprogramming process mediated by 
OKSM, probably through the control of c-Myc transcription, cell senescence and chromatinic 
regulation [50]. This effect is also obtained if the expression of PATZ1 is induced during the 
reprogramming, not at the beginning. Partial depletion (heterozygotesKnockout), however, 
promotes the genesis of iPSCs by the downregulation of repressive histones and the up-
regulation of active histones, leading to the creation of a more open and accessible chromatin. 
Moreover, it has been seen that PATZ1+/- manages to pass the Ink4a/Arflocus, a locus of 
senescence. The total loss of PATZ1 (PATZ1-/-) finally leads to cellular senescence and therefore 
the blockage of cellular reprogramming.During cell reprogramming, PATZ1 acts by blocking the 
expression of c-Myc which, in turn, counteract the inhibitory action of PATZ1 and it appears that, 
when over-expressed, the protein with the "Zn finger" domain would cause an over-expression 
of p16, a senescence marker, and p53. Gene expression studies on murine embryo fibroblasts at 
various levels of expression of PATZ1 (+/+, +/- and -/-) have shown that a number of genes are 
up-regulated, while others are down-regulated; with the study of Genica Ontology it has been 
seen that these are transcription factors, many of which are related to development, cellular 
differentiation, but also to neurophysiology, factors implicated in the induction of mesenchima-
epithelium transition or chromatinic regulation (histones deacetylaseHdac 2,4,11 are down-
regulated with PATZ1 shutdown, while acetylases Hat1 and Kat2a are up-regulated).The 
mechanism by which the heterozygous form (+ ;-) could overcome the obstacle represented by 
senescence is mediated by histone acetylation which promotes an open chromatin state 
accessible to the activation of the transcriptional network of pluripotency. In fact, in the Ink4a 
locus (gene implicated in senescence), the inactive H3K27me3 histamine (so called because of 
lysine 27 tri-methylate) is down-regulated. 
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From these observations it is concluded that PATZ1 has an effect that is dependent not only by 
the context, but also by the concentration. 
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AIMS AND SCOPES  
The aim of the present work was to characterize the immunohistochemicalexpression of 
PATZ1 protein in gliomas, compare it with the normal brain and evaluate its possible 
prognostic role. Furthermore, we studied its co-localization with stem cell markers by 
the help of immunofluorescence and cell cultures.  And finally, we assessed the eventual 
correlation of PATZ1 with the G-protein coupled receptor CXCR4.  
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METHODS 
 
1. Tissue specimens  
45 patients diagnosed with glioblastoma and 22 with oligodendroglioma were included 
in the study. They had all undergone a complete excision of the tumor at first surgery. All 
the cases were identified between 2004 and 2013 and the diagnoses were made in 
accordance with the 2007 WHO classification [5]. This time interval was chosen in order 
to ensure a clinical follow-up period of at least 2 years for each identified case. All the 
cases were reviewed to evaluate adequate representative formalin-fixed paraffin-
embedded tissue in order to perform immunohistochemical assay. We excluded those 
cases for which data of outcome were unavailable and for which diagnostic tissue was 
insufficient. Informed consent for the scientific use of biological material was obtained 
from all patients and the work has been approved by the local Ethical Committee (CEI 
203/15 of 12/11/2015).  
2. Immunohistochemical analysis  
4 μm sections were used for immunohistochemistry. Sections were dewaxed in xylene, 
hydrated in graded series of alcohol and subjected to heat-induced antigen retrieval. 
After blocking endogenous peroxidase activity, the tissue was incubated with antibody 
anti- PATZ1 (polyclonal rabbit, R1P1 [51]; 1: 500 dilution, overnight incubation). 
Subsequently, the slices were rinsed and incubated with the biotinylated secondary 15  
antibody, at room temperature, for 30 minutes. The bound antibody complexes were 
stained for 3-5 minutes or until appropriate for microscopic examination with 
diaminobenzidine, and slides were then counterstained with hematoxylin (30s) and 
mounted. All slices were reviewed by two experienced pathologists (M.L.D., E.G.).  
The assessment of PATZ1 (nuclear) staining was based on the percentage of positive 
cells: no signal was set as “0”, ≤10% as “+”, >10% and <50% as “++” and ≥50% as “+++”. 
We defined high expression of PATZ1 as >10% of cells staining positive, and low 
expression as ≤10% of cells staining positive.  
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3. Immunofluorescence and confocal microscopy  
For multiple-labeling immunofluorescence, tissues slides were dewaxed, hydrated and 
antigen retrieval was performed using Dewax and HIER Buffer L (Thermo Fisher 
Scientific, Cheshire, UK) as previously described [52]. They were incubated with the 
mixture of two primary antibodies anti-NESTIN (mouse monoclonal, sc23927, Santa 
Cruz Biotechnology, Santa Cruz, CA; 1:200 dilution, 90 minutes incubation) and anti-
PATZ1 (rabbit polyclonal, R1P1; 1: 500 dilution, overnight incubation) or anti PATZ1 
and anti-OCT-3/4 (mouse monoclonal, sc-5279 Santa Cruz Biotechnology; 1:100 
dilution, 90 minutes incubation) in 1% BSA in PBS-T in a humified chamber overnight at 
4°C. Fluorescent secondary antibodies, raised against different species (Alexa Fluor 594, 
with red signal, against rabbit and Alexa Fluor 488, with green signal, against mouse), 
were used to locate the antigen/primary antibody complexes. Counter staining was 
made with Hoechst 33258 (nuclear blue staining) present in mounting medium 
(PBS:Glycerol = 1:1). Experiments were carried out on an inverted and motorized 
microscope (Axio Observer Z.1) equipped with a 63x/1.4 Plan-Apochromat objective. 
The attached laser scanning unit (LSM 700 4x pigtailed laser 405-639, Zeiss, Jena, 
Germany) enabled confocal imaging. For excitation, 405 nm, 488 nm and 555 nm lasers 
were used. Fluorescence emission was revealed by MBS 405/488/555/639 for Hoechst 
33258, Alexa Fluor 488 and Alexa Fluor 594. Triple staining immunoflourescence 
images were acquired separately in the blue, green and red channels at a resolution of 
1024x1024 pixels, with the confocal pinhole set to one Airy unit and then saved in TIFF 
format.  
To assess the stemness of GSCs, NANOG (rabbit polyclonal, ab80892 Abcam; 1:200 
dilution), SOX-2 (mouse polyclonal, AB5603 Millipore; 1:500 dilution), OCT-4 (rabbit 
polyclonal, sc-5279 Santa Cruz; 1:250 dilution) and NESTIN (mouse monoclonal, 92590 
Chemicon; 1:100 dilution) expression was evaluated. PATZ1 (rabbit polyclonal, R1P1, 
1:500 dilution) expression was analyzed as well. Briefly, cells were fixed in 4% 
paraformaldehyde for 20 minutes at room temperature (RT) and permeabilized for 10 
minutes at RT with 0.1% Triton X-100 (Sigma-Aldrich) before exposing them to primary 
antibodies, that were incubated over-night at 4°C. Subsequently, Alexa Fluor 488 and 
Alexa Fluor 555 dyes labeled secondary antibodies against mouse and rabbit, 
respectively, diluted 1:800 in PBS, were employed for 1 hour in a humidified chamber at 
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37°C (Molecular Probe, Invitrogen). Lastly, slides were mounted using Vectashield 
(Vector), as mounting medium, added with 0.1 μg/ml DAPI (Sigma) for nuclear staining. 
Images were acquired utilizing a live cell imaging dedicated system consisting of a Leica 
DMI 6000B microscope connected to a Leica DFC350FX camera (Leica Microsystems, 
Wetzlar, Germany) and equipped with a 63X/1.4 oil immersion objective or a 40X/1.25 
oil immersion objective. Adobe Photoshop software was utilized to compose and overlay 
the images and to adjust contrast.  
4. Cell cultures and transfection  
The independent ethic committee of the AziendaOspedaliero-Universitaria of Udine has 
approved the research (Consents 102/2011/Sper and 196/2014/Em). Informed written 
consents were obtained from patients and all clinical investigations have been 
conducted according to the principles expressed in the Declaration of Helsinki.  
GSCs (n=11) were isolated as previously described [53,54]. Briefly, human GBM samples 
were mechanically-enzymatically dissociated and cells less than 40μm in diameter 
cultured on laminin-coated dishes in a growing medium composed as follows: 
Neurobasal-A medium (Gibco by Invitrogen, Carlsbad, CA), 2mM L-glutamine (Sigma-
Aldrich, St. Louis, MO,), 1X N2 supplement (Gibco by Invitrogen), 25mg/ml Insulin, 
Penicillin-streptomycin, 100mg/ml human apo-trasferrin (Sigma- Aldrich), 1X B-27 
supplement (Gibco by Invitrogen), 20 ng/ml recombinant human basic fibroblast 
growth factor (h-FGF-basic) (Peprotech, Rocky Hill, NJ), 20 ng/ ml human epidermal 
growth factor (h-EGF) (Peprotech). Then cells were cultured in an incubator at 37°C, 
5%O2/5%CO2 and analyzed at the third passage in culture. From six GBM samples we 
isolated, in addition to GSCs, the matched non-stem tumor cells by growing dissociated 
cells in DMEM (Gibco by Invitrogen) supplemented with 10% fetal bovine serum (FBS) 
(EuroClone, Pero, Italy) and 100 U/ml Penicillin 100 μg/ml Streptomycin. Cells were 
grown in an incubator at 37°C, 5%O2/5% CO2 and analyzed at the first passage in 
culture.  
Human GBM U87MG (American Type Culture Collection, ATCC no. HTB-14), were grown 
in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% FBS. To obtain 
tumorspheres, U87MG cells were grown at low density (2000 cells/ml) in Stem cell 
medium (SM) [DMEM-F12 supplemented with 1% B27 (Sigma-Aldrich), 10 ng/ml h-FGF 
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(Sigma-Aldrich) and 20 ng/ml h-EGF (Sigma-Aldrich)] for 12 days. U87MG 
tumorspheres were induced to differentiate through the addiction of 10% FBS in SM 
medium. The cancer stem cell phenotype of these  
www.impactjournals.com/oncotarget 16  
cells was confirmed by assessing the expression of the stemness markers PDGFRß, 
NANOG and SOX-2.  
VS-GB primary cell culture was derived from GBM specimens and grown as described 
previously [55]. They were transiently transfected by JetPRIME (Polyplus transfections, 
Illkirch, France) with 10 μg of HA-PATZ1 plasmid encoding for PATZ1 variant 4 or 10 μg 
of the empty vector pCEFL-HA as negative control, according to manufacturer’s 
instruction.  
5. RNA extraction and quantitative real time (qRT)-PCR  
Total RNA from cells was purified by TRIzol (Invitrogen). After digestion of the residual 
genomic DNA by DNase I (Qiagen, Milano, Italy), RNA was reverse transcribed by 
SuperScript III cDNA synthesis kit (Invitrogen). cDNA was used to perform qPCR 
reactions with SYBR Green Master Mix gene expression kit (Biorad, Segrate, Italy) in 96-
well plates with a LightCycler 480 system (Roche, Monza, Italy). The PCR conditions 
were as follow: 95°C for 3 minutes; 45 cycles at 95°C for 10 seconds, 60°C for 20 seconds 
and 72°C for 60 seconds. Primer pairs used (300 nm each) were as follows: PATZ1 (5’-
TACATCTGCCAGAGCTGTGG- 3’/5’-TGCACCTGCTTGATATGTCC-3’); GAPDH (5’- 
GTCTCCTCTGACTTCAACAGCG-3’/5’-ACCACCCTG TTGCTGTAGCCAA-3’). CXCR4 (5’-
TGAGAAG CATGACGGACAAG-3′/5’-AGGGAAGCGTGATGAC AAAG-3′); β-ACTIN (5’-
CAAGAGATGGCCAC GGCTGCT-3’/5’-TCCTTCTGCATCCTGTCGGCA-3’). Gene expression 
changes were calculated using the 2(-Delta Delta C(T)) method [56].  
6. Protein extraction and western blot analysis  
Cells were lysed in buffer containing 1% Nonidet P-40, 1 mmol/liter EDTA, 50 
mmol/liter Tris-HCl (pH 7.5), and 150 mmol/liter NaCl supplemented with Complete 
protease inhibitors (Roche). Total proteins were resolved in a 10-12% polyacrylamide 
gel under denaturing conditions and transferred to nitrocellulose filters for Western blot 
analyses. Membranes were blocked with 5% BSA in TBS and incubated with the primary 
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antibodies. Membranes were then incubated with the horseradish peroxidase–
conjugated secondary antibody (1:3.000) and the reaction was detected with a Western 
blotting detection system (enhanced chemiluminescence; GE Healthcare). The primary 
antibodies used were: anti-PATZ1 [51]; anti-NESTIN (sc- 23927, Santa Cruz 
Biotechnology, Santa Cruz, CA); anti- PDGFRβ (3169, Cell Signaling Technology, Boston, 
MA); anti-NANOG (sc-134218, Santa Cruz Biotechnology); anti- SOX2 (sc-20088, Santa 
Cruz Biotechnology); anti-CXCR4 (C8727, Sigma-Aldrich). To ascertain that equal 
amounts of protein were loaded, the membranes were incubated with anti-ACTIN (sc-
1616-R, Santa Cruz Biotechnology) or anti-VINCULIN (sc-7649, Santa Cruz 
Biotechnology) antibodies.  
7. Data mining  
For PATZ1 mRNA expression analysis and correlation with clinical, molecular and cell 
phenotype, the Genomics Analysis and Visualization platform (http://r2.amc.nl) was 
used with the following datasets: 1) GSE9385 [57], including 6 adult non diseased brain, 
26 glioblastomas and 21 oligodendrogliomas,; 2) GSE8049 [58], including 9 different 
glioblastoma-derived neurosphere cultures in two biological replicates; 3) GSE15209 
[59], including stem cells derived from 7 GBMs, 2 oligoastrocytomas, 5 normal fetuses 
and primary biopsies from 6 normal brains; 4) GSE18015 [60], including 8 gliomas 
sorted for CD133 expression; 5) the TCGA dataset Tumor Glioblastoma - 540 - MAS5.0 - 
u133a (n = 540) (http://cancergenome.nih. gov), including 85 samples sub-classified in 
classical (n = 17), mesenchymal (n = 27), neural (n = 17) and proneural (n = 24) GBM 
[7], to correlate PATZ1 expression to GBM subtype and specific gene signatures. The last 
dataset was also used for Overall and Progression-free survival analysis using the scan 
cut-off mode based on median PATZ1 expression and specifying the proneural track 
subset.  
8. Statistical analysis and Kaplan-Meier survival curves  
The Fisher’s exact test was used to evaluate the correlations between PATZ1 score and 
the clinical variables (age, gender, site, oligodendroglioma grading).  
All correlations within the TCGA and other public datasets were assessed by Pearson’s 
χ2 test or one-way analysis of variance (ANOVA), through the R2 platform 
(http://r2.amc.nl).  
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Kaplan-Meier survival curves were used to analyze OS and PFS, and statistical 
significance was assessed by the log-rank test. In Figure 6A, the stratification of 
High/Low PATZ1 was based on the percentage of cells expressing nuclear PATZ1 
protein by immunohistochemistry (High: > 50%; Low: < 50%). The stratification of 
High/Low PATZ1 and High/Low CXCR4 in the TCGA dataset was based on RNA 
expression using a cutoff of 100.6 and 197.7, according to the scan function of the R2 
platform used, where an optimum survival cutoff is established based on statistical 
testing (log-rank test).  
PATZ1 expression on human derived stem cells was expressed as mean ± standard 
deviation. Comparisons between two groups were performed by paired or unpaired t 
test, as appropriate.  
All statistical analyses were performed using GraphPad Prism 5 software (GraphPad 
Software, La Jolla, CA). A probability (p) value less than 0.05 was considered statistically 
significant. 
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RESULTS 
1. PATZ1 is expressed in human gliomas and is enriched in the proneural subtype  
Using paraffin embedded sections generated from surgical specimens collected at the 
Department of Advanced Biomedical Sciences, Pathology Section, of the University of Naples 
Federico II, we analysed by immunohistochemistry PATZ1 expression in 45 grade IV GBM, 22 
oligodendrogliomas (10 grade III and 12 grade II) and 26 perilesional normal brain 
parenchymas. Of 45 GBM patients included in the study, 30 were males and 15 females, aged 
between 26 and 81 years. The lesion was mainly localized in the temporal lobe in 22 cases, 
parietal in 11 cases, frontal in 9 cases, occipital in 2 cases and 1 in the corpus callosum 
(Supplementary Table 1). Of 22 oligodendroglioma patients 15 were males and 7 females, aging 
from 22 to 69 years. 14 cases were frontal, 4 temporal, 3 occipital and 1 was an intramedullary 
metastasis (Supplementary Table 2).  
We have observed that PATZ1 protein is expressed in neurons (mainly in the nucleus) but not in 
glial cells of all perilesional normal brain tissues (Figure 5A), whereas it is expressed in a high 
percentage of GBM (69%) with a mainnuclear, but sometimes cytoplasmic localization (Figure 
5B, Supplementary Table 1) and oligodendrogliomas (54%) (Supplementary Table 2).  
 
 
 
Among positive samples, PATZ1 immunoreactivity was variable in both GBM and 
oligodendrogliomas, including samples scored + (<10%), ++ (>10% <50%), +++ (≥ 50%). Of 31 
GBM positive for PATZ1 staining, 17 displayed +, 9 ++ and 5 +++ score (Figure 6A–D, 
Supplementary Table 1). Among the 12 oligodendrogliomas expressing PATZ1, 4 cases had +, 5 
++ and 3 +++ score (Figure 6E–6H, Supplementary Table 2). Among the assessed 
clinicopathological features of GBM (age, gender, site), a high significant correlation and a trend 
Figure 5:  Immunohistochemicaldetection of PATZ1 in human GBM and perilesional normal 
cortex. (A) Perilesional normal cortex: only neurons stain positively, mainly in the nucleus, while glial 
cells are negative. (B) Representative GBM: most of neoplastic cells are positive. Original 
magnification: 40x 
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to be correlated with PATZ1 expression was present in the male gender (p = 0.0028) and 
younger patients (p = 0.0695), respectively. Moreover, a statistically significant correlation was 
observed between PATZ1 immunoreactivity and grading (p = 0.0286) in oligodendrogliomas 
(Table 1).  
 
 
 
 
 
 
Figure 6:  Immunoreactivity score in GBM and oligodendrogliomas stained for PATZ1. (A) 
Representative GBM scored 0.(B) Representative GBM scored +. (C)Representative GBM scored ++. 
(D)Representative GBM scored +++. (E)Representativeoligodendrogliomascored 
0.(F)Representativeoligodendrogliomascored +. (G)Representativeoligodendrogliomascored ++. 
(H)Representativeoligodendrogliomascored +++. Originalmagnification: 40x 
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By analysing public datasets through the R2: genomic Analysis and Visualization platform 
(http:// r2.amc.nl), we confirmed in an independent sample cohort of 6 adult non diseased 
brains, 26 GBMs and 21 oligodendrogliomas [57] that PATZ1 is significantly more expressed in 
gliomas (including GBMs and oligodendrogliomas) compared to non diseased brain samples 
(Figure 7A). Moreover, in a data set from the Tumor Cancer Genomic Atlas (TCGA), including 85 
samples, sub-classified in classical (n = 17), mesenchymal (n = 27), neural (n = 17) and 
proneural (n = 24) GBM, we found that PATZ1 expression specifically correlates with the 
molecular subtype, being highest in proneural and lowest in mesenchymal subtype, with 
significant differences between each subtype (Figure 7B). Consistently, by studying the gene 
signature correlated with the expression of PATZ1 in the context of GBM, we found that PATZ1 
expression positively associates with proneural genes, including SOX2, OLIG2, DLL3,NOTCH1, 
PDGFRαand many others, while negatively associates with the mesenchymal marker CD44 and 
many other genes characterizing the mesenchymal signature (Table 2 and Supplementary Table 
3). 
Taken together protein and gene expression data, PATZ1 is overexpressed in gliomas compared 
to normal glia and appears as a specific biomarker of the proneural GBM sub-type. 
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Figure 7: In silico meta-analysis of PATZ1 expression in human GBM tissues and cell lines. (A) 
Box-plot comparing PATZ1 expression in normal brain (NB) and gliomas of different grade (G). The 
data were analyzed by one-way analysis of variance (ANOVA) through the R2 web platform(B) Box-plot 
showing PATZ1 expression in the different GBM subtypes and statistical analysis of the differences 
among them. C= Classical, M= Mesenchymal, N= Neural, P=Proneural. The data were analyzed by one-
way analysis of variance (ANOVA) through the R2 web platform. (C)On the left, YY-plot in GSCs 
(ordered by PATZ1 expression). The cells are divided in two groups as indicated in the figure. On the 
right, box-plot comparing PATZ1 expression in the two groups. (D) YY-plot correlating PATZ1 and 
PROM1 expression in stem cell derived from GBM (n=7), oligoastrocytoma (n=2), normal human foetus 
(n=5) and primary biopses of non-malignantbrain tissue (n=6). Significance of correlation (inbox) was 
analyzed by Pearson’s χ2 test through the R2 web platform (http://r2.amc.nl). (E) Box-plot comparing 
PATZ1 expression in primary GBM sorted for CD133 expression (negative/positive). The data were 
analyzed by one-way analysis of variance (ANOVA) through the R2 web platform. *, p<0.05; **, p<0.01; 
***, p<0.001; ****, p<0.0001. Datasets for each cohort of samples are indicated in the figure with 
relative reference in brackets. 2log og PATZ1= logarithmic values of PATZ1 expression with base of 2 
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Fig.8: PATZ1 expression in GSC cultures. (A) Representative phase contrast pictures of human 
glioma cells cultured in media selective (GSC, right panels) or not (DIFF , left panels) for the growth 
of glioma stem cells. The upper-right panel displays GSC growing as neurosphere, while the lower-
right panel displays GSCs growing in adhesion. Scale bar: 100 µm. (B) Gene expression changes of 
PATZ1 in human glioma cells grown  in media selective (GSC) or not (DIFF) for the growth of GSC, as 
assessed by qRT-PCR. Data are presented as mean±SD. (C) Gene expression changesof PATZ1in GSC 
growing in adhesion (Adherent) or in suspension (Sphere), as assessed by qRT-PCR. Data are 
presented as mean±SD.(D) Representative immunofluorescence images depicting the expression of 
OCT4, NANOG, SOX-2 and NESTIN in GSC growing either in adhesion (GSC adherent, lower panels) or 
in suspensions (GSC shere, upper panels). Nuclei are depicted by the blue fluorescence of DAPI. Scale 
bar: 20 µm. (E) Representative confocal immunofluorescence image (merge image) showing the 
expression of PATZ1 (yellow fluorescence) and Nestin (red fluorescence) in GSCs. Nuceli are 
depicetd by the blue fluorescence of DAPI. Single immunodetection of either PATZ1 or Nestin in the 
inset areal, and digital merge of teh images, are shown in the middle. Negative control obtained by 
omitting the primary antibodies is shown on the right. Scale bar: 20 µm. 
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2. PATZ1 is preferentially expressed in glioma stem cells  
It has been recently reported that a proneural-like gene expression signature is characteristic of 
GSCs characterized by a full stem phenotype (Gsf lines), growth as floating spheres, CD133 
expression and multipotency, while a mesenchymal-like gene expression signature is associated 
with GSCs characterized by a restricted stem phenotype (Gsr lines), adherent growth, no CD133 
expression and limited differentiation [58, 61, 62]. Consistently, by analysing the expression 
profiles of the 9 GSCs and relative sub-clones isolated and characterized by Günter and 
colleagues (4 with Gsf phenotype and 5 with Gsr phenotype) we found that PATZ1 is 
significantly enriched in Gsf-GSCs compared with Gsr-GSCs (Figure 7C). The association of 
PATZ1 expression with CD133 expression was further confirmed by the analysis of two separate 
experimental datasets consisting of cell lines established from 7 GBMs, 2 oligoastrocytomas and 
5 normal foetuses plus primary biopsies from 6 normal brains [28], and 8 fresh primary and non 
cultured GBMs [29], where PATZ1 expression is highly correlated with that of PROM1 (the gene 
encoding prominin-1/ CD133) (Figure 7D), and is significantly enriched in the CD133+ 
compared to the CD133- subpopulation (Figure 7E). Consistently, in these cells lines PATZ1 also 
correlates with markers of oligodendrocyte precursor cells, including SOX8, OLIG1, OLIG2, and 
NKX2.2, and of the proneural phenotype, such as DLL3, OLIG2 and SOX2 (Supplementary Table 
4). All together these results indicate that PATZ1 is preferentially expressed in GSCs in 
comparison with matched non-GSCs, and is particularly enriched in 
proneuralversusmesenchymal subtype.  
To validate the in silicoresults, we analyzed PATZ1 expression in 6 GSCs (3 growing in adhesion 
and 3 growing as spheres in laminin-coated dishes) isolated from patients affected by GBM in 
comparison with matched non-stem tumor cells (Figure 8A). The results confirmed an enriched 
expression of PATZ1 in stem versus non-stem matched samples (P < 0.05; Figure 8B). The 
differences do not reach the statistical significance if we consider each group (sphere forming 
and growing in adhesion GSCs) singularly, likely because of the low number of samples, but they 
have a trend to be higher in GSCs compared to matched non-stem tumor cells (data not shown). 
Moreover, PATZ1 expression was also analyzed in 5 more GBM-derived GSCs, for a total of 11 
GSCs, which were sub-divided in two groups on the basis of their growth capacity in laminin-
coated dishes (sphere/adherent). As shown in Figure 8C, and consistently with data shown in 
Figure 3C, PATZ1 expression was highly enriched in GSCs growing as spheres compared to GSCs 
growing adherent (P < 0.01). All isolated GSCs, independently from their modality to grow in 
laminin-coated dishes, expressed markers of stemness, as confirmed by immunofluorescence 
analysis (Figure 8D), at higher levels compared with matched DIFF cells (data not shown). 
Immunofluorescence analysis confirmed expression of PATZ1 in GSC growing either as spheres 
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or in adhesion and their colocalizationwith the stemness marker Nestin (Figure 8E and data not 
shown). PATZ1 expression here appears mainly nuclear but a speckled cytosolic expression can 
be observed as previously described in other cancer cell types [27,51]. We also used the GBM 
cell lines U87MG to isolate GSC and analyze PATZ1 expression in comparison with matched bulk 
and differentiated cells (Supplementary Figure 1). PATZ1 protein expression resulted enriched 
in GSC versus both bulk and differentiated matched cells and correlated with expression of 
platelet-derived growth factor receptor β (PDGFRβ), a stem cell-specific marker in human GBM 
[63].  
To further confirm in vivo the association of PATZ1 with the stem cell compartment of the GBM, 
we performed immunofluorescence labeling with antibodies anti-PATZ1 and GSC markers, 
including NESTIN and OCT-4, in 5 GBMs positive for PATZ1 expression. As shown in Figure 9, 
PATZ1 (red nuclear signal) was co-expressed with NESTIN (green cytoplasmic signal) in a sub-
population of neoplastic cells. In these cells co-localization of OCT-4 (green nuclear signal) with 
PATZ1 was also evident. 
 
 
 
 
 
Figure 9: PATZ1 localization in the stem cell compartment of GBM. Representative confocal 
microscopy images of GBM (two samples with high PATZ1 score (+++) and GBM-associated normal 
tissues stained with anti-NESTIN (A,E), antiOCT4 (I) and antiPATZ1 (B,F,J). (D, H, L) Merge images 
showing co-localization of PATZ1 with either NESTIN or OCT-4. Scale bar: 20 µm 
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3. PATZ1 expression levels predict survival of GBM patients  
The proneural GBM subtype is characterized by a trend toward longer survival, but is totally 
unresponsiveto aggressive treatment with concurrent chemo- and radiotherapy [7]. Consistent 
with the enrichment of PATZ1 in the proneural subtype, we showed in our local cohort of 
gliomas, that patients with low PATZ1 score (0/+) had a worse overall survival (OS) than 
patients with high PATZ1 score (++/+++) (HR = 2.525, 95% CI = 1.208- 5.280, p = 0.0138) 
(Figure 10A). The median OS for 16 patients with high PATZ1 was 36 months, in contrast to 12 
months for 28 patients with low or absent PATZ1. Similarly, when we extended survival 
analyses to a larger cohort of GBM samples (n = 85), in which all subtypes were similarly 
represented (GBM – TCGA - 540), both OS and progression-free survival (PFS) were significantly 
correlated to PATZ1 expression, being worse in patients expressing low levels of PATZ1 
(Supplementary Figure 2). In this same cohort of samples proneural GBMs have longer survival 
compared with mesenchymal subtype (Supplementary Figure 2, Panel C). Interestingly, also 
when we restricted the analysis to the proneural subset of GBM, Kaplan Meyer survival curves, 
followed by log-rank test, showed that PATZ1 expression stratifies these patients (n = 24) in two 
statistically different subgroups where low PATZ1 has worse OS (HR = 3.191, 95% CI = 2.355-
14.31, p = 0.001) and PFS (HR = 3.595, 95% CI = 2.785-19.06, p = 0.0006) (Figure 10B–10C). The 
median OS for 10 patients with high PATZ1 expression was 53 months, in contrast to 10 months 
for 14 patients with low PATZ1. Even more strikingly, the median PFS for patients with high 
PATZ1 was 63 months versus 6 months for patients with low PATZ1. Moreover, the 5-year PFS 
was about 40% for proneural GBM patients with high PATZ1 versus 0 with low PATZ1. In the 
same group of patients, using a multivariate Cox regression analysis, including known 
prognostic factors, such as age at diagnosis and methylation of the MGMT gene, low expression 
of PATZ1 resulted an independent prognostic factor for OS survival (HR= 0.2886, 95% CI = 
0.0982-0.8482, p = 0.0246) and PFS (HR = 0.2458, 95% CI = 0.0802-0.7534, p = 0.0146).  
These data suggest that PATZ1 expression has a crucial impact on outcome of GBM patients with 
a proneural classification, and could be used as an independent prognostic marker to predict 
survival and response to treatment.  
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Figure 10: PATZ1 expression negatively correlates with survival in GBM patients. (A) Overall 
(OS) Kaplan-Meier survival curves of GBM patients shown in Suppelmentary Table 1, stratified by 
protein levels of PATZ1, as indicated. (B) OS and (C) Progression-Free (PFS) Kaplan-Meier curves of 
the proneural subset of GBM patients form the TCGA dataset shown in Figure 4B. Note that patients 
with lower PATZ1 expression have a worse survival rate than patients with higher PATZ1 as assessed 
by Log-Rank test 
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4. PATZ1 downregulatesCXCR4 expression in GBM 
Remarkably, low PATZ1 samples shown in Figure 6B and 6C were mostly characterized (11 out 
of 14) by increased expression of the G-protein coupled receptor CXCR4 (Supplementary Table 
5), which has been shown to induce and assist in the maintenance of a mesenchymal expression 
profile in GBM cells [64] and is overexpressed in CD133+ cells from human GBMs resistant to 
chemotherapy [65]. Indeed, we found that CXCR4 was a high significant prognostic and 
predictive factor in proneural GBM, were high CXCR4 patients show a worstoutcome considering 
both OS and PFS survival curves (Figure 11A–11B), and negatively correlated with PATZ1 in 
these patients (r = -0.449; p = 0.03) (Figure 11C). A similar negative correlation between PATZ1 
and CXCR4 was also observed in GSCs (Supplementary Figure 3).  
In order to investigate a possible role of PATZ1 in downregulatingCXCR4 gene expression in 
GBM cells, we transiently transfected the VS-GB cells, a GBM-derived primary cell line that does 
not express PATZ1, with a plasmid expressing PATZ1, and measured CXCR4 mRNA and protein 
levels by qRT-PCR and western blot, respectively (Figure 11D). A significant decrease of both 
mRNA and protein levels was observed in cells expressing PATZ1 compared to empty vector-
transfected control, supporting an inhibitory role of PATZ1 on CXCR4 expression. This is 
consistent with data extracted from the Trafac homology server, showing that the CXCR4 
promoter harbor consensus sequence for PATZ1 [66], and with data extracted by our previous 
analysis of Patz1-knockout mouse embryonic fibroblasts [67], showing that Patz1-null mouse 
embryonic fibroblasts express a 4-fold change increase of Cxcr4 compared to wild-type 
littermate controls.  
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Figure 11: CXCR4 expression correlates positively with survival and negatively with PATZ1 in 
proneural GBM patients. (A) Overall survival (OS) and (B) Progression- Free survival (PFS) Kaplan-
Meier curves of the patients shown in Figure 7B-7C (proneural subset of the TCGA dataset of GBM). 
Note that patients with higher CXCR4 expression have worse survival rates than patients with lower 
CXCR4, as assessed by Log-Rank test. (C) YY-plots correlating PATZ1 and CXCR4 expression in the 
proneural GBMs shown in A and B. Significance of correlation (inbox) was analyzed by Pearson’s χ2 
test through the R2 web platform (http://r2.amc.nl). (D) VS-GB cells were transiently transfected with 
10 µg PATZ1 expressing plasmid, and endogenous CXCR4 mRNA was measured 48h later by qRT-PCR. 
CXCR4 mRNA levels were normalized for endogenous β-actin levels. The mean ±SE of three 
independent experiments, each in duplicate, is reported ***, P=0.0001. PATZ1 and CXCR4 protein 
expression is shown on the top by western blot analysis, using vinculin detection as a loading control. 
Densitometric analysis by Image J software was applied: relative expression levels of CXCR4, 
compared to empty vector-transfected control and normalized with respect to vinculin, are indicated 
on the top of the blot.  
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DISCUSSION 
One of the most important hallmarks of GBM is the marked heterogeneity within and across 
these tumors, which has been attributed to cancer cell plasticity [68]. According to the cancer 
stem-cell model some cancers are organized into a hierarchy of subpopulations of tumorigenic 
cancer stem cells, which drive tumor growth, therapy resistance and disease progression. It is 
therefore imperative to clarify the markers that can be used to identify these cells and the 
context in which they work [69]. It has been recently proposed that patient-derived 
glioblastoma stem-like cells (GSCs) can be sub-divided in two main groups, one characterized by 
a proneural-like phenotype and the other showing a mesenchymal-like phenotype according to 
the molecular subtype classification of the TCGA [7,61]. Phenotypically, proneural GSCs exhibit 
non-adherent sphere forming growth in vitro and circumscribed, non-invasive growth in vivo. In 
contrast, mesenchymal cells grow semi-adherently in vitro and show invasive growth in vivo 
[61,70]. Accordingly, patients with proneural GBM have a trend toward longer survival [7], 
whereas patients with mesenchymal GBM show the worst outcome [71].  
In this study we analyzed expression of the Kruppel-type Zinc Finger transcription factor PATZ1 
in GBM and oligodedrogliomas, finding it was highly expressed in a significant number of cases, 
whereas it was undetectable in normal glia. Moreover, we showed that PATZ1 is expressed in 
GSCs both in vitro (in GBM-derived stem cells) and in vivo (human tissue specimens), is 
downregulated in differentiated cells from the same tumor as compared to GSCs, and its 
expression is higher in GSCs growing as spheres (likely proneural) than in GSCs growing as 
adherent cells (likely mesenchymal). These observations were validated and completed in 
independent glioma datasets, finding a significant overlap of high PATZ1 expression with the 
proneural subtype and conversely of low PATZ1 expression with the mesenchymal subtype in 
both GBMs and GSCs. Since PATZ1 has been described as an inhibitor of cell proliferation in 
some cancer cell contexts [13,27,72], we would expect that GSCs growing as spheres that 
express higher levels of PATZ1 compared to GSCs growing in adhesion may proliferate less. 
However, sincethere are no differences in the proliferation rate between GSCs growing as 
spheres and those growing as adherent cells [58], we concluded that PATZ1 is not associated 
with proliferation in these cells. Interestingly, confocal microscopy analysis of human GBM 
specimens showed that PATZ1 was expressed in the NESTIN+ subpopulation, which has been 
recently shown to be crucial for tumor recurrence after treatment with the chemotherapeutic 
agent temozolomide[32].   
Finally, we characterized the prognostic impact of PATZ1 expression first in our local cases of 
GBM,finding a significant worst outcome in patients showing absent or low levels of PATZ1 
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(<10% positive cells), suggesting it may be used as a prognostic marker. Then, extending the 
analysis to the TCGA dataset, including samples subclassified in the four subtypes described by 
Verhaak et al. [7], the capacity of PATZ1 to discriminate GBM patients with different prognosis 
was significantly shown also in the proneural subtype, where low levels of PATZ1 correlate with 
a worst outcome in both overall and progression-free survival curves, independently from other 
known prognostic factors, such as MGMT promoter methylation and age at diagnosis. Therefore, 
despite PATZ1 is enriched in the proneural subtype, there are proneural GBMs that express low 
levels of PATZ1 that are associated with a shorter patients survival. This is consistent with the 
already described intra-subtype heterogeneity of GBMs, which highlights the importance of 
finding new markers able to further sub-classify each subtype [68]. 
Since PATZ1 loss/downregulation has been associated with the acquisition of a mesenchymal 
phenotype in cancer cells [27], and the mesenchymal phenotype in GBMs is associated with the 
poorest prognosis and most aggressive phenotype, with advantage in proliferative capacity and 
neovascularization [71,73], we speculate that a subset of proneural GBMs may be more 
aggressive due to the downregulation of PATZ1 and consequent activation of a mesenchymal 
program. Consistent with this hypothesis, we found that in the proneural subset there was a 
75% of negative concordance (r = -0.44; p = 0.03) between PATZ1 and CXCR4, whose 
overexpression is an outcome common to multiple mechanisms of Epithelial-Mesenchymal 
Transition (EMT) induction in GBM and directly involved in determining the EMT phenotype 
[74]. Interestingly, according to the Trafac homology server, the CXCR4 promoter harbors 
consensus sequence for PATZ1 [66], and Patz1-null mouse embryonic fibroblasts express a 4-
fold change increase of Cxcr4 compared to wild-type littermate controls [67]. Therefore, it is 
possible that PATZ1 could be directly involved in CXCR4 silencing. Indeed, it has been 
hypothesized that factors associated with the more stem-like phenotype may account for CXCR4 
expression in GBM [62], and we provided evidence that PATZ1 could be one of these factors: in 
VS-GB cells, a primary GBM cell line that does not express endogenous PATZ1, overexpression of 
PATZ1 leads to downregulation of CXCR4. Further experiments are ongoing in our laboratory to 
explore the possibility of a direct role of PATZ1 on the CXCR4 promoter in GBM as well as in 
other cancer-derived cell lines, where PATZ1 appears involved in counteracting EMT. According 
to current opinions envisaging a parallel between dedifferentiation of cancer cells and 
reprogramming of somatic cells [75], the transdifferentiation of tumor cells from proneural to 
mesenchymal may imply a reprogramming process thatleads differentiated cells to reacquire the 
capacity to differentiate into different cells. This is consistent with our previous results showing 
that PATZ1 plays an inhibitory role in the reprogramming process [67], and suggests a potential 
PATZ1 inhibitory role on the transition from the mesenchymal to the proneuralphenotype. 
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However, further functional experiments are needed to demonstrate the involvement of the 
PATZ1-CXCR4 axis in the proneural-to-mesenchymalphenotipic switch.  
In conclusion, we describe PATZ1 as a novel biomarker of GBM and GSCs, differentially 
expressed among GBM and GSC subtypes and able to further subdivide the proneural GBM 
subtype in two populations with different overall and progression free survival. As PATZ1 has 
been proven an important transcription factor involved in stem cell pluripotency[76], it is 
encouraging to see that the proneural type of GBM, characterized by a stem-like signature, has 
higher expression of PATZ1 compared to other types. Finally, this finding may explain the 
paradox that the proneural type of GBM resist standard therapeutic caused by the cancer stem 
cells maintained by PATZ1 involved transcription factor networks while at the same time PATZ1 
restrict the proneural type of GBM to differentiation into mesenchymal type. 
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Supplementary Figure 1: PATZ1 in U87MG  cells growing as spheres 
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Supplementary Figure 2:  Survival curves in GBM patients from the TCGA dataset 
Supplementary Figure 3:  PATZ1/CXCR4 correlation in GSCs 
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Supplementary Table 1:  Clinicopathological features and PATZ1 expression of 45 
glioblastomas (local cohort analyzed by IHC) 
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Supplementary Table 2:  Clinicopathological features and PATZ1 expression of 22 
oligodendrogliomas (local cohort analyzed by IHC) 
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Supplementary Table 3:  Other correlations between PATZ1 and the mesencymal signature in 
GBMa
 
Supplementary Table 4:  Oligodendrocyte precursor and proneural gene expression 
correlations with PATZ1 in GBM-derived stem cells
 
69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 5:  Molecular and clinical features in proneural GBM (TCGA dataset)
 
